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ABSTRACT OF DISSERTATION
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Professor Linda Pike, Chairperson

The epidermal growth factor (EGF) receptor is a classical receptor tyrosine kinase
that mediates cellular processes such as proliferation, migration, and differentiation in
response to growth factor stimulation. Crystal structures of the EGF receptor suggest that
its activation is associated with extensive conformational changes in both the
extracellular and intracellular domains. However, evidence of these structural dynamics
in intact cells has been lacking. This thesis describes the characterization of sequential
ligand-induced conformational changes in the EGF receptor in live cells in real time
using luciferase fragment complementation imaging. We find that these conformational
changes are unique to the full-length activated EGF receptor. These studies identified a
novel conformational change that was dependent on MAP kinase activation and
desensitization of the EGF receptor. It has been unclear how MAP kinase desensitizes
the EGF receptor following activation. Mutational analysis was done to identify residues
involved in the MAP kinase-mediated EGF receptor desensitization.

We use these

analyses to provide a structural explanation for the MAP kinase-mediated desensitization
of the EGF receptor. The luciferase complementation assay was further utilized to test
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the ability of different ligands for the EGF receptor family to induce dimer formation and
intracellular domain conformational changes.
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CHAPTER 1. Introduction to the EGF Receptor Family
Discovery of EGF and its Receptor
The epidermal growth factor (EGF) was first discovered in 1962 by Professor
Stanley Cohen. The route to this discovery began with the discovery of nerve growth
factor (NGF). While working in the lab of Professor Viktor Hamburger, Dr. Rita LeviMontalcini observed that when a fragment of mouse tumor (Sarcoma 180) was grafted
onto the body wall of chick embryos, both sympathetic and sensory fibers entered the
tumor and exteneded to tissues that they normally should not reach (1). After several
confirmatory experiments, Dr. Levi-Montalcini and Professor Hamburger hypothesized
that this phenomenon was due to a diffusable agent that was released from the tumor,
resulting in the stimulation of nerve cell growth (2, 3).
Professor Stanley Cohen, a postdoc in the Hamburger lab at the time, further
advanced the remarkable story when he discovered that crude extract from the mouse
tumors could be inactivated by protease but not Dnase or RNase. These observations led
him to think that the disffusable agent was a protein (4), but the possibility of it being a
virus was also raised by Professor Arthur Kornberg. In an attempt to test the virus
hypothesis, Professor Stanley Cohen used partially purified phosphodiesterase from
snake venom (which would have degraded all known nucleic acids including those of
viruses) in the absence and presence of his crude tumor extract to examine the effect on
chick ganglions in culture. To his surprise, partially purified phosphodiesterase alone
resulted in a massive growth of nerve fibers in a single day. Further experiments showed
that this growth resulted from the presence of an additional protein in the impure
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phosphodiesterase preparation, and that it in its purified form was much more potent in
stimulating nerve growth. This protein was the nerve growth factor or NGF (5).
Puzzled by the lack of an apparent connection between nerve growth, tumors and
snake venom, Professor Cohen wondered about the source of the snake venom— the
salivary glands. He subsequently tested crude extracts of the salivary gland from male
mice and observed that these mice-extracts were just as potent in inducing nerve
outgrowth. Futhermore, when these crude extracts were injected daily into newborn mice
the sympathetic ganglion were enlarged. Even more surprisingly, the mice opened their
eyes 5-7 days earlier than normal and their teeth errupted earlier, a phenomenon that
could not be induced by purified NGF..
Professor Cohen went on to pursue the question why crude extracts from the male
mouse salivary gland induced early eyelid opening in the mouse as a faculty at
Vanderbilt. By examining histological sections of the eyelid area from control and
treated animals, it was clear that early eyelid opening was due to enhanced epidermal
growth and keratinization. The 53-amino acid disulfide linked protein responsible was
purified from the mouse salivary gland using the eyelid-opening functional assay and was
initially referred to as tooth-lid factor (6).
To address whether this tooth-lid factor was acting directly or indirectly via a
secondary mechanism, the tooth-lid factor was added directly to organ cultures of chick
embryonic skin. This led to a direct effect in which there was an increase in both
epidermal cell number and size, resulting in a renaming of tooth-lid factor to epidermal
growth factor (EGF) (7).
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The prevailing theory at the time was that protein hormones do not enter cells, but
rather bind to cell surface receptors to exert their effect and then dissociate. The next
major discovery was the identificaiton and isolation of the receptor for EGF.

An

explosion of research into the EGF receptor then followed. Among the major discoveries
were that 1) EGF addition to A431 cell membrane preparations resulted in incorporation
of 32P-ATP into the protein of membranes (8); 2) many proteins were phosphorylated in
A431 membranes, particularly a protein of 170kDa (9); 3) the purified 170kDa protein
bound EGF, had protein kinase activity that was dependent on ATP and EGF and was
itself phosphorylated (10-15); and finally that 4) the EGF receptor was a tyrosine kinase
(16).
The initial identification of EGF and its receptor won Professor Cohen the nobel
prize in 1986. His groundbreaking research into the field of growth factors and their
receptors has shaped nearly 50 years of research to date, and has led to the identification
of nearly 60 receptor tyrosine kinases. The remainder of this introduction will focus on
the biology of the EGF receptor.

Nomenclature and Domain Organization of the EGF Receptor Family
The EGF receptor (ErbB1/HER1) is the founding member of the ErbB or human
EGF receptor (HER) subfamily of receptor tyrosine kinases. This subfamily consists of
three additional members: ErbB2/HER2/Neu, ErbB3/HER3, and ErbB4/HER4.

The

ErbB nomenclature derives from the high homology between the family members and the
avian erythroblastosis virus v-erb-B transforming protein (17). The ErbB members are
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highly homologous (40-45% sequence identity) (18) and all share similar domain
organizations.
The EGF receptor consists of an extracellular ligand-binding domain, a singlepass ɑ-helical transmembrane domain, and an intracellular domain with tyrosine kinase
activity (19) (Figure 1.1). Approximately half of the receptor constitutes the extracellular
domain (amino acids 1-621). The remainder of the EGF receptor is comprised of the
transmembrane domain (amino acids 622-644), the intracellular juxtamembrane domain
(amino acids 645-685), the tyrosine kinase domain (amino acids 686-960), and the Cterminal tail (amino acids 961-1186) (Figure 1.1).

Ligand-Induced EGF Receptor Dimer Formation
The canonical view of EGF receptor activation postulates that in the absence of
ligand, the receptor exists as an inactive monomer in cell membranes (challenges to this
hypothesis will be discussed later in the introduction). Upon ligand binding to the
extracellular domain, EGF receptor dimers are formed leading to stimulation of the
protein tyrosine kinase activity (Figure 1.2). Initial studies indicating that the EGF
receptor dimerizes upon ligand binding demonstrated that addition of EGF leads to
conversion of the receptor from a low molecular weight to a higher molecular weight
state (20). Additionally, covalently cross-linking
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I-EGF to its receptor results in a

slower electrophoretic migration, which is competed by addition of unlabeled EGF (20).
Further chemical crosslinking studies showed that EGF induces EGF receptor
dimerization in Triton X-100-solubilized receptor preparations (21, 22), membrane
preparations (23), and in intact cells (24-26).
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Dimerization of the EGF receptor stimulates the protein tyrosine kinase activity,
which leads to an intermolecular autophosphorylation mechanism of tyrosine residues on
the C-terminal tail of the receptor (Figure 1.2). Several lines of evidence support the
intermolecular phosphorylation mechanism as opposed to an intramolecular or truly selfphosphorylation process. First, EGF receptor cross-linking using bivalent antibodies
stimulates receptor autophosphorylation, with no autophosphorylation observed in the
absence of antibodies or using monovalent forms of the antibodies (27, 28). Second,
simply immobilizing the EGF receptor on solid matrices prevents EGF from activating
the receptor kinase activity (27). Finally, in experiments where cells expressed a kinasedead EGF receptor and a kinase-active EGF receptor that lacks the amino-terminal 63
amino acids (and two autphosphorylation sites), the kinase-dead EGF receptor was
observed to be in the phosphorylated state. This phosphorylation could only result from
an intermolecular process mediated by the truncated/kinase-active EGF receptor since the
kinase-dead EGF receptor completely lacks catalytic activity (29, 30). Taken together,
these data support the ligand-induced dimerization and activation mechanism for the EGF
receptor.

Structure-Based Activation Mechanism for the EGF Receptor
Recent crystal structures of the EGF receptor extracellular domain have provided
invaluable insights into the structural aspects of the activation mechanism. The EGF
receptor extracellular domain consists of four subdomains: I, II, III, and IV (Figure 1.3).
Subdomains I and III are homologous and together form the primary ligand binding site
(red in Figure 1.3). Subdomains II and IV are homologous cysteine-rich regions (19)
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(green in Figure 1.3). In the absence of ligand, the EGF receptor monomer exists in a
tethered/closed conformation (31) (Figure 1.3). The EGF receptor monomer is held in
this tethered conformation primarily through a β-hairpin/loop in subdomain II that
interacts with a similar loop in subdomain IV. One of the required residues for this
interaction is Y246 in subdomain II (31).

This tethered conformation of the EGF

receptor is thought to have low affinity for ligand because the ligand cannot
simultaneously bind subdomains I and III (31).
Ligand binding to the EGF receptor disrupts the intramolecular tether and
promotes a dramatic conformational change in which the EGF receptor adopts an
open/extended conformation (31-33) (Figure 1.3). The β-hairpin/loop from subdomain
II, referred to as the dimerization arm, mediates formation of back-to-back EGF receptor
dimer (32, 33) (Figure 1.3). In the extended, dimerized conformation, Y246 is crucial to
formation of the EGF receptor/EGF receptor intermolecular contacts in the dimer.
Mutation of this residue to D, F, or W abolishes EGF receptor dimer formation as
measured by chemical crosslinking (34).

Moreover, the integrity of this residue is

required to observe EGF receptor autophosphorylation, providing a structural basis for
the observed intermolecular phosphorylation mechanism (34).
Recently it has been demonstrated that the EGF receptor kinase domain can also
form dimers (35). X-ray crystallography work has shown that the kinase domain of the
EGF receptor forms an asymmetric dimer in which the N-lobe of one kinase contacts the
C-lobe of a second kinase (35) (Figure 1.4). In this configuration, one of the monomers
(acceptor in Figure 1.4) becomes activated and is able to phosphorylate the C-terminal
tail of the second monomer (donor in Figure 1.4). Mutation of residues in the dimer
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interface of either the N-lobe (eg L680N) or the C-lobe (eg V924R) block the ability of
EGF to stimulate kinase activation (35).

Together these data imply an allosteric

mechanism for activation of the EGF receptor kinase domain. Through an unknown
mechanism, these kinase domains may re-order, so that phosphorylation of the other
kinase monomer in the dimer can occur (donor becomes acceptor and vice versa in Figure
1.4).
The intracellular juxtamembrane region has also been hypothesized to play a
critical role in activating the kinase domain (Figure 1.1). Thiel and Carpenter first
demonstrated the necessity for this domain by utilizing an intracellular domain (ICD)
construct that is constitutively autophosphorylated (36). Deletion of amino acids 645-662
or 645-676 resulted in a dramatic reduction in EGF receptor autophosphorylation.
Similar results were obtained when these deletion mutants were introduced into the
ligand-regulated full-length EGF receptor that was expressed in NIH 3T3 cells.
Structurally, insight on the juxtamembrane region was first gained from the
asymmetric kinase domain crystal structure of ErbB4 bound to a thienopyrimidine analog
inhibitor, a structure that included the C-terminal portion of the juxtamembrane region of
ErbB4 (EGF receptor amino acids 664-961) (37). Further analysis of the asymmetric
dimer in this structure by Jura et al. showed that the juxtamembrane region of the
acceptor kinase forms a cradle around the C-lobe of the donor kinase in the asymmetric
unit (Figure 1.5A) (38). A recent crystal structure of the EGF receptor kinase domain
where the entire juxtamembrane region (amino acids 652-994) was visible revealed a
similar “cradling” orientation (Figure 1.5B) (39). In both of these reports, mutagenesis
of the ICD construct (39) or the full-length EGF receptor (38) in the C-terminal portion
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of the juxtamembrane domain (amino acids 664-682) significantly impaired
autophosphorylation of the EGF receptor. In addition, Jura et al. demonstrated using
mutagenesis that residues in the C-lobe of the donor kinase that contact the
juxtamembrane

domain

of

the

acceptor

kinase

autophosphorylation of the EGF receptor (38).

are

also

required

for

full

These findings suggest that the

juxtamembrane region is important for formation of the asymmetric dimer interface and
required for full activation of the EGF receptor.
While there is ample structural information for the extracellular and tyrosine
kinase domains of the EGF receptor, there is little structural information for the Cterminal tail. This is likely due to the conformational flexibility of this region. Indeed,
hydrodynamic studies have shown that upon autophosphorylation of the C-terminal tail,
the EGF receptor intracellular domain adopts a more extended conformation than in the
absence of autphosphorylation (40). Additional studies using FRET suggest that the Cterminal tail and the EGF receptor tyrosine kinase domain separate to form a more
extended molecule following autophosphorylation (41).

Higher Order EGF Receptor Oligomers
There is evidence that the EGF receptor forms higher order oligomers both in the
absence and presence of ligand. Using image correlation microscopy of an EGF receptorGFP chimera, studies have shown that the EGF receptor undergoes a dimer-tetramer
transition upon stimulation with ligand (42). Recent studies from our lab using
fluorescence intensity cluster analysis support the notion that the EGF receptor may exist
in preformed dimers and higher order oligomers in the absence of ligand (43).
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Studies utilizing FRET microscopy with fluorescently labeled EGF demonstrated
that the receptor bound EGF molecules are capable of significant energy transfer.
However, these data contradicted the known structure of EGF receptor dimers (Figure
1.3), where the two bound EGF molecules are too far apart (100Å) to undergo the
observed significant energy transfer. Thus, the authors hypothesized that FRET occurred
due to clustering of the EGF receptor, most likely in side-by-side tetramers (44). Other
studies using lifetime-based FRET microscopy suggest that in the absence of ligand, the
EGF receptor may exist in large clusters, with up to 30 receptors per cluster (45). These
clusters may enable rapid receptor activation on ligand binding.
Together these studies provide evidence for the existence of a higher-order
signaling complex within the EGF receptor system. The nature of higher order EGF
receptor oligomers is not fully understood and the structural requirements for such an
oligomer have not been addressed.

Ligands for the EGF Receptor Family
In order to engage the EGF receptor in signaling inside the cell, the receptor must
first be activated by a small, soluble growth factor outside the cell. There are 11 known
ligands that bind to the extracellular domains of the EGF receptor family (46, 47) (Figure
1.6A).

These ligands can be subdivided into three groups based on their receptor

specificity: 1) EGF, TGF-α, Amphiregulin (AR), and Epigen all bind the EGF receptor,
2) Betacellulin (BTC), Heparin-binding EGF, and Epiregulin all bind the EGF receptor
and ErbB4, 3) the Neuregulins (of which there are multiple isoforms) bind to ErbB3 or
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ErbB4 (46-48). It is interesting to note that no ligand has yet been found that binds to
ErbB2.
All ligands for the EGF receptor family are synthesized as transmembrane
precursors that are cleaved by the ADAM (A Disintegrin And Metalloproteinase) family
of metalloproteinases (49). This cleavage leads to release of the “mature” or soluble
protein into the cell matrix or cell culture (Figure 1.6B). Ligands for the EGF receptor
family also have at least one EGF-like motif, which is defined by the presence of six
spatially conserved cysteine residues (CX7 CX4-5 CX10-13 CXCX8 C). These cysteines
then form three disulifide bonds (C1-3, C2-4, C5-6) (49).
The ligands for the EGF receptor family have different binding affinity and
specificity (47, 50). They also induce different phosphorylation patterns of the signaling
tyrosine residues which consequently leads to diversification of signaling pathways
activated and gene expression patterns (47). While these differential outputs are not yet
fully understood, part of the distinction may lie in the conformation of the receptor bound
to ligand. The subdomain II dimerization arm in the EGF receptor extracellular domain
adopts slightly different conformations when bound to EGF versus TGF-α, which may
reflect differences in one of the ligand binding subdomains (III)

(32, 33, 47).

Differences in ligand-binding to the extracellular domain my be transmitted to the
intracellular domain, resulting in slightly different interfaces for the tyrosine kinase
domains and eventually leading to the observed differential outputs (47).
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Ligand-Induced EGF Receptor Signaling
Ligand binding to the EGF receptor promotes a conformational change in the
extracellular domain that exposes residues essential for dimerization (31-34, 51-53).
Formation of EGF receptor dimers brings into close proximity the tyrosine kinase
domains so that they can form the activating asymmetric dimer interface (35, 46, 54).
This enhances the catalytic activity of the EGF receptor kinase, resulting in
autophosphorylation in trans on five regulatory tyrosine residues in the ~200 amino acid
C-terminal tail (55-60) (Figure 1.7A). In addition to autophsophorylation, the EGF
receptor can also be transphosphorylated on its tyrosine residues by other kinases, such as
Src (61-63) (Figure 1.7A).
The phosphorylated C-terminal tail tyrosine residues of the EGF receptor serve as
association sites for signaling or adaptor proteins. The pattern and sequence context of
the phosphorylated tyrosine residues discriminates which Src homology 2 (SH2) and
phosphotyrosine binding (PTB) domain-containing proteins bind to the EGF receptor (56,
64) (Figure 1.7A). SH2 modules are typically 100 amino acids long and recognize
phosphorylated tyrosines in the context of the 3-6 amino acids downstream of the
phosphorylated tyrosine. In contrast, PTB modules are typically 150 amino acids long
and recognize phosphorylated tyrosines by the amino acids just upstream (64, 65). The
SH2 and PTB domain-containing proteins that bind to the EGF receptor phosphorylated
tyrosine residues ultimately determines which signaling pathways are activated and the
biological outcome from the external cue (cell proliferation, survival, migration, etc.) (48,
57, 64, 66). The SH2 and PTB domain-containing proteins serve as adaptors, enabling
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EGF receptor signaling inside the cell. Association with the EGF receptor facilitates
formation of an ordered multicomponent signaling complex (48, 56, 57, 64, 66).
Several signaling pathways are activated by the EGF receptor, but the focus of
this introduction will be on the Ras/mitogen activated protein (MAP) kinase pathway.
Following autophosphorylation of the EGF receptor on tyrosine residues, growth factor
receptor-bound protein 2 (Grb2) docks directly to tyrosines 1068 or 1086, or associates
indirectly via Shc (56, 67-69) (Figure 1.7A and B). Grb2 is constitutively bound to the
guanine nucleotide exchange factor Son of Sevenless (SOS) (70) so that binding of Grb2
to the EGF receptor relocalizes the complex to the plasma membrane. This causes
exchange of GDP for GTP on the membrane-bound protein Ras, thereby activating Ras
(71-74). Activated Ras in turn activates the serine-threonine kinase Raf (75-77), which
phosphorylates the threonine/tyrosine kinase MEK (78, 79). Finally, MEK activates
MAP kinase through phosphorylation on threonine and tyrosine residues, inducing
nuclear translocation and the phosphorylation and activation of nuclear transcription
factors that lead to cellular proliferation (56, 69, 80).

Mechanism of EGF Receptor Deactivation
Following activation, negative regulation of EGF receptor signaling must ensue to
prevent “over-signaling” from the receptor. Failure in proper EGF receptor de-regulation
often leads to heightened oncogenic potential (81). Long-term regulation is mediated by
internalization and subsequent irreversible degradation of the receptor (82-84). This
process was first described by Carpenter and Cohen in studies demonstrating that
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EGF binds to the EGF receptor and is subsequently removed from the cell surface and
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degraded by lysosomes (85). Long-term regulation of EGF receptor signaling, later
termed “EGF-induced down-regulation of the EGF receptor”, serves as a major negative
regulatory mechanism (84).
Independent of receptor internalization and degradation, the EGF receptor also
undergoes a rapid negative regulatory component, termed desensitization, that is
associated with a loss of protein tyrosine kinase activity (86-88). Desensitization can
occur through binding of negative regulatory proteins to the EGF receptor. The best
characterized example is the protein MIG-6 (also known as gene 33 or receptorassociated late transducer/RALT).

MIG-6 is transcriptionally induced by the EGF

receptor via the Ras pathway and has been shown through crystallography work to bind
to the C-lobe of the EGF receptor kinase domain to block formation of the activating
asymmetric dimer (81, 89-92). Binding of MIG-6 to the EGF receptor effectively blocks
activation of the EGF receptor without blocking the catalytic activity.
In addition to specific negative regulators, several proteins activated by the EGF
receptor signaling pathways also play significant roles in the desensitization process.
Previous work suggests that phosphorylation of the EGF receptor on two threonine
residues within the intracellular juxtamembrane region may be involved in the rapid loss
of tyrosine kinase activity (93, 94). Of these two sites, the major site of threonine
phosphorylation on the EGF receptor is Thr-669 (95). Phosphorylation of this site is
mediated by a feedback loop: the EGF receptor activates MAP kinase, which in turn
directly phosphorylates the EGF receptor on Thr-669 (96-98). Mutation of Thr-669 to
Ala is associated enhanced EGF receptor phosphorylation (94). These data suggest that
phosphorylation of Thr-669 is associated with EGF receptor desensitization.
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The

mechanism by which phosphorylated Thr-669 blocks receptor kinase activity is not
understood. Overall, the pathways and proteins that negatively regulate EGF receptor
signaling are poorly understood and much work remains to understand how these
pathways function and how they may be exploited or modified to evolve new therapies
targeting the EGF receptor.
The work presented in this thesis will examine several conformational changes in
the EGF receptor, as well as the implications of these conformational changes. Chapter 2
will describe how a luciferase fragment complementation imaging assay was developed
and utilized in the context of the EGF receptor system to follow ligand-induced
conformation changes. This type of analysis has not been possible using existing assays.
One of the major implications of these results will be described in Chapter 3, with the
mechanistic explanation for MAP kinase-mediated EGF receptor desensitization.
Finally, Chapter 4 will delve into one aspect of the wide-range of utility of luciferase
fragment complementation imaging of the EGF receptor by focusing on the effects of
EGF-like growth factors. A discussion of the global implications of these results and
potential future studies based on these results will be addressed in Chapter 5.
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Figure 1.1. Domain organization of the EGF
receptor. The extracellular domain consists of four
subdomains (I-IV). This is followed by an ɑ-helical
transmembrane domain and then the intracellular
juxtamembrane domain. The tyrosine kinase domain
contains the catalytic activity of the receptor, while
the C-terminal tail contains regulatory tyrosine
residues (52).

Figure 1.2. Schematic representation for the ligand-induced dimerization and
activation of the EGF receptor. In the absence of ligand, the EGF receptor is thought to
exist as an inactive monomer (left panel). Binding of ligand induces EGF receptor dimer
formation, bringing into proximity the tyrosine kinase domains of the EGF receptor and
resulting in enhanced kinase activity (right panel). This results in autophosphorylation in
trans of tyrosine residues in the C-terminal tail of the receptor, as well as phosphorylation
of several protein substrates.
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Figure 1.3. Schematic representation of the EGF receptor extracellular domain
monomer and dimer. In the absence of ligand, the EGFR monomer is held in a
tethered/closed conformation through contacts between subdomains II and IV. Ligand
binding between subdomains I and III induces a dramatic conformational change that
disrupts the intramolecular tether and exposes a dimerization arm in subdomain II. This
dimerization arm mediates the formation of a back-to-back EGFR dimer. Figure adapted
from Burgess et al. (53).

N-lobe
Donor
C-lobe
Acceptor

Donor

Acceptor

Figure 1.4. Schematic representation of the EGF receptor kinase domain
asymmetric dimer. Upon ligand binding to the extracellular domain, the EGF receptor
undergoes a conformational change that results in formation of an extracellular domain
dimer. This dimer is thought to bring into close contact the kinase domains from each
monomer. X-ray crystallography and mutational studies have demonstrated that the
asymmetric dimer is required for EGF stimulation of kinase activity. Figure adapted
from Zhang et al. (35).
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Figure 1.5. Crystal structure of the intracellular juxtamembrane and kinase
domains of ErbB4 (Her4) and the EGF receptor. A) Cartoon depiction of the ErbB4
(Her4) asymmetric dimer including 20 amino acids from the intracellular juxtamembrane
region. The cradle formed by the juxtamembrane domain of the acceptor kinase is
magnified in the right panel (38). B) Crystal structure of the kinase-dead (K721M) EGF
receptor juxtamembrane and kinase domains in the asymmetric dimer. Similar to ErbB4,
the juxtamembrane region of the acceptor kinase cradles the C-lobe of the donor kinase
(39).

17

A

B

Figure 1.6. Ligands for the EGF receptor family. A) Ven diagram depicting the
specifity of various EGF-like ligands for members of the EGF receptor family (47). B)
ADAMs (A Disintegrin Activated Metalloproteinase) are responsible for the proteolytic
processing of the transmembrane precursors for the EGF receptor family of ligands. This
releases a soluble “mature” peptide growth factor that binds to members of the EGF
receptor family (46).
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B

Figure 1.7. Ligand-induced EGF receptor autophosphorylation and downstream
signaling. A) Schematic of the EGF receptor C-terminal tail phosphorylation sites and
association of SH2 and PTB domain-containing proteins. Autophosphorylation sites are
shown in red, while transphosphorytion sites mediated by Src are shown in blue (64). B)
Simplified view of the signaling pathways activated by ligand binding to the EGF
receptor (69).
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CHAPTER 2. Luciferase Fragment Complementation Imaging of Conformational
Changes in the EGF Receptor
Introduction
Activation of the EGF receptor is thought to be associated with several dramatic
conformational changes in the extracellular and kinase domains, as well as the C-terminal
tail (31-33, 35, 40, 99). While evidence from crystal structures and purified systems
suggests that the EGF receptor undergoes several conformational changes during the
process of activation, these changes have not been observed in intact cells. Thus, the
relevance of these findings to the physiological situation is not clear. This problem was
addressed using a luciferase fragment complementation imaging assay (100) to image
EGF receptor dimerization and ligand induced conformational changes in real time in live
cells.
In the context of an EGF receptor lacking the entire cytoplasmic domain,
luciferase fragment complementation accurately reports on the kinetics of EGF receptor
dimerization.

When used with the full-length EGF receptor, the system reveals

sequential conformational changes in the EGF receptor that are dependent on receptor
autophosphorylation as well as phosphorylation of the receptor by MAP kinase. Our data
demonstrate the utility of the luciferase system for in vivo imaging of EGF receptor
dimerization and intracellular domain conformational changes. The data presented in this
chapter suggest that phosphorylation of the receptor by MAP kinase determines the final
conformation adopted by the activated EGF receptor.
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Results
EGF induces a rapid increase in luciferase complementation in ΔC-EGFR-NLuc/CLuc
cells
The firefly luciferase complementation system utilizes two fragments of
luciferase termed NLuc and CLuc. These fragments are inactive by themselves but are
capable of reconstituting an active luciferase if the fragments are brought into close
proximity (100, 101). Initially, the luciferase fragments were independently fused to the
C-terminus of an EGF receptor lacking the entire cytoplasmic domain yielding the ΔCEGFR-NLuc and ΔC-EGFR-CLuc cDNA constructs.

CHO-K1 Tet-On cells were

transfected with ΔC-EGFR-NLuc and a line that stably expressed ΔC-EGFR-NLuc in a
doxycycline-inducible manner was selected. Twenty four hours prior to use, these cells
were transiently transfected with ΔC-EGFR-CLuc. These cells are referred to as ΔCEGFR-NLuc/CLuc CHO cells.
For imaging experiments, cells were first incubated with luciferin for 20 min at
37ºC to allow equilibration of the intracellular and extracellular pools of this substrate.
This preincubation assures a stable baseline during the subsequent 20 min observation
period (Figure 2.1A). Luciferase activity was measured by monitoring the photon flux
from ΔC-EGFR-NLuc/CLuc co-expressing CHO cells.

Readings were taken

approximately every 30 sec, providing a continuous readout of luciferase activity through
bioluminescence imaging of live cells.
Luciferase activity was detectable in cells co-expressing ΔC-EGFR-NLuc and
ΔC-EGFR-CLuc even in the absence of added EGF (Figure 2.1A open circles). This
suggests the presence of receptor-receptor interactions in the basal state. The addition of
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10 nM EGF led to a rapid increase in light production that plateaued between 10 and 15
min (Figure 2.1A, closed circles). Both the rate and extent of ligand-induced dimer
formation were dependent on the concentration of EGF (Figure 2.1B). This increase in
luciferase complementation following EGF stimulation is consistent with the canonical
model of EGF-induced dimerization of its receptor (20). Importantly, the rate of dimer
formation detected by luciferase fragment complementation was similar to the rate of
125

I-EGF binding observed in these cells (Figure 2.1C, 1nM EGF: 0.14 ± 0.015 min-1 for

luciferase versus 0.15 ± 0.02 min-1 for binding; 10 nM EGF: 0.30 ± 0.03 min-1 for
luciferase versus 0.42 ± 0.13 min-1 for binding).

This indicates that this imaging

technique accurately reflects the kinetics of ligand-induced dimerization of the EGF
receptor.
EGF elicits a rapid but transient decrease in luciferase activity in full-length EGFRNLuc/CLuc cells
To assess the contribution of the cytoplasmic domain of the EGF receptor to
receptor-receptor interactions, the NLuc and CLuc fragments were independently fused
to the C-terminus of the full-length EGF receptor. To ensure that equal levels of the two
chimeric receptors were expressed, a double-stable CHO-K1 Tet-On cell line was
established that will be referred to as the EGFR-NLuc/CLuc cell line. In this cell line,
EGFR-CLuc was constitutively expressed while EGFR-NLuc was expressed from a
doxycycline inducible plasmid. This allowed adjustment of EGFR-NLuc expression
levels to match those of EGFR-CLuc.
As shown in Figure 2.2A, Scatchard analysis of

125

I-EGF binding to the

uninduced EGFR-NLuc/CLuc cells indicated that EGFR-CLuc was expressed at a level
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of ~100,000 receptors per cell. When the cells were treated with 1 µg/ml doxycycline,
binding experiments demonstrated the presence of ~200,000 EGF receptors per cell.
These data suggest that under these conditions, EGFR-NLuc and EGFR-CLuc are
expressed at roughly equivalent levels of approximately 100,000 receptors/cell. As can
be seen from Figure 2.2A, both Scatchard plots were curvilinear, demonstrating that these
receptor fusion proteins retain this characteristic feature of EGF binding to the wild type
receptor (102).
The effect of the luciferase fragments on the kinase activity of the EGF receptor
was determined independently in CHO cells that expressed only the EGFR-NLuc or the
EGFR-CLuc receptors.

The data in Figure 2.2B show that EGF stimulated the

autophosphorylation of both EGFR-NLuc and EGFR-CLuc, indicating that both receptors
retain kinase function. EGFR-NLuc showed two distinct bands, both of which were
phosphorylated and both of which react with anti-luciferase antibodies (Figure 2.2C).
This suggests that the lower molecular weight form is not the result of proteolytic
removal of the luciferase fragment. It is possible that differences in glycosylation may be
responsible for the different forms. Both NLuc- and CLuc-EGF receptors mediated the
activation of MAP kinase (Figure 2.2B). Thus, addition of the luciferase fragments did
not substantially alter the biochemical behavior of the EGF receptor.
When EGFR-NLuc/CLuc cells were incubated with luciferin, light production
was observed in the absence of EGF (Figure 2.3A). At least a portion of this basal light
production is due to receptor-receptor specific interactions, since the basal luciferase
activity is decreased upon transient transfection of cDNA for the unlabeled EGF receptor
(Figure 2.4). In contrast to the results obtained with the truncated ΔC-EGF receptor,
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addition of EGF to EGFR-NLuc/CLuc cells resulted in a rapid, but transient, decrease in
luciferase activity (Figure 2.3B-2.3G). The decrease was observed at the earliest time
point following EGF addition and reached a nadir 2 to 4 min after EGF stimulation.
Subsequently, light production recovered to essentially the same level as that observed
prior to EGF addition.
Because EGF induces a variety of changes in ion transport and metabolic
pathways, it was possible that the decrease in light production observed after the addition
of EGF was due to changes in pH or some other metabolite within the cells. To examine
this possibility, HeLa cells that express endogenous EGF receptors were transfected with
FRB-NLuc and its binding partner CLuc-FKBP (100). Treatment of these cells with
rapamycin induces interaction of FRB and FKBP leading to enhanced luciferase activity.
In this system, addition of EGF failed to alter the level of complementation stimulated by
rapamycin (Figure 2.3H). This suggests that the EGF-induced decrease in luciferase
activity observed in the EGFR-NLuc/CLuc cells is not due to a non-specific effect on
luciferase fragment complementation arising from metabolic changes stimulated by the
growth factor.
The decrease in luciferase activity is dependent on EGF receptor kinase activity
Figure

2.5

compares

the

time

course

of

EGF-stimulated

receptor

autophosphorylation with that of the EGF-induced decrease in luciferase activity in
EGFR-NLuc/CLuc cells. As can be seen from the figure, maximal autophosphorylation
occurred within 30 sec after the addition of EGF. By contrast, the decrease in luciferase
activity required 2 to 4 min to reach its nadir. Thus, receptor activation precedes the
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agonist-induced decrease in luciferase activity.

This suggests that the decrease in

luciferase activity might be a consequence of receptor tyrosine kinase activation.
To assess the involvement of receptor kinase activity in the decreased luciferase
complementation, EGFR-NLuc/CLuc cells were incubated with 5 µM erlotinib or 10 µM
AG1478 to inhibit receptor tyrosine kinase activity. Inhibition of EGF receptor kinase
activity was confirmed using Western blot analysis with an anti-phosphotyrosine
antibody (Figure 2.6). Treatment with erlotinib or AG1478 induced a ~3-fold increase in
basal luciferase activity indicating that they enhanced the interaction between EGF
receptors under resting conditions (Figure 2.7A). This increase was specific for the EGF
receptor, since treatment of HeLa cells expressing FRB-NLuc and CLuc-FKBP with
erlotinib or AG1478 did not alter light production (Figure 2.7B).

As expected,

stimulation with EGF led to a transient decrease in luciferase activity in control cells
(Figure 2.7C and D). However, this effect was largely eliminated in cells pre-treated
with erlotinib or AG1478 (Figure 2.7C and D).
To further test the hypothesis that an active EGF receptor kinase is required to
observe the decrease in luciferase activity, EGF receptor autophosphorylation was
indirectly blocked. Cells were treated with inhibitors of proteins that modulate EGF
receptor function. 12-O-tetradecanoylphorbol 13-acetate (TPA) has been reported to
block activation of the EGF receptor kinase (103). This was confirmed by pre-treatment
of cells with TPA followed by addition of 10 nM EGF and Western blot with an antiphosphotyrosine antibody (Figure 2.8A). When compared to control cells, TPA does not
influence the basal light production in the luciferase complementation assay (Figure
2.8B). Similar to the EGF receptor-specific tyrosine kinase inhibitors, addition of TPA in
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the luciferase complementation assay was also able to block the transient decrease and
recovery in light production that was observed after 10 nM EGF stimulation (Figure
2.8C). EGF receptor autphosphorylation can also be inhibited by calmodulin antagonists
such as calmidazolium, although the exact mechanism remains unknown (104-106). Pretreatment with calmidazolium decreased EGF receptor autophosphoyrlation as measured
by Western blot by ~50% (Figure 2.9A). Pre-treatment with calmidazolium increased the
basal light production in EGFR-NLuc/CLuc CHO cells by ~6-fold (Figure 2.9B).
Calmidazolium did not affect the light production in HeLa cells expressing FRB-NLuc
and CLuc-FKBP (Figure 2.9C). Pre-treatment with calmidazolium, followed by addition
of 10 nM EGF partially blocked the decrease in luciferase activity, consistent with an
incomplete inhibition of EGF receptor autophosphorylation (Figure 2.9D). These results
further support the hypothesis that an active EGF receptor kinase is required to observe
the decrease in luciferase activity.
Because the effect of erlotinib, AG1478, and calmidazolium on basal luciferase
complementation complicated the interpretation of the effects on the EGF-stimulated
decrease in luciferase activity, the requirement for EGF receptor tyrosine kinase activity
was further examined using the K721A-EGF receptor. The K721A mutation abolishes
the tyrosine kinase activity of the EGF receptor (107). The NLuc and CLuc fragments
were fused to the C-terminus of the K721A-EGF receptor and were transiently
transfected into CHO cells. As was seen for the wild type EGF receptor, erlotinib
enhanced basal luciferase activity in this kinase-dead EGF receptor mutant (Figure
2.10A). However, in contrast to the situation with wild type receptor, addition of EGF to
the K721A-EGF receptor led to an increase in luciferase activity (Figure 2.10B), similar
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to that seen in the ΔC-EGF receptor (Figure 2.1). Erlotinib enhanced the EGF-stimulated
increase in luciferase activity in the K721A-EGF receptor system suggesting that the
effect of this tyrosine kinase inhibitor is independent of the effects elicited by EGF.
These data confirm the involvement of receptor tyrosine kinase activity in the ligandinduced decrease in luciferase complementation.
The observed decrease in luciferase activity is consistent with the hypothesis that
EGF induces a conformational change in the receptor that leads to separation of the
luciferase fragments. To determine whether the EGF-stimulated decrease in luciferase
complementation was due to movement of the C-terminal tails of the receptors or
involved changes in the relative positions of the kinase domains, the luciferase fragments
were fused to an EGF receptor truncated at residue 973 just beyond the kinase domain.
The constructs were expressed in CHO cells. Luciferase activity was detectable in these
cells in the absence of EGF (Figure 2.11A). Treatment of the c′973-EGFR-NLuc/CLuc
cells with EGF led to a decrease in luciferase activity that was somewhat smaller than
that observed for the wild type EGF receptor (Figure 2.11B). While there was some
recovery of luciferase activity over time, it was slower and less extensive than that seen
for the wild type receptor. Thus, while the effect of EGF was apparent in the truncated
receptor it was significantly dampened compared to that observed with the wild type
receptor. These data suggest that EGF induces movement of the kinase domains relative
to each other but in the full-length receptor, this is amplified by conformational changes
that lead to the separation of the C-terminal tails of the receptors.
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MAP kinase activity is required for the recovery of luciferase complementation
The recovery of luciferase activity after treatment of EGFR-NLuc/CLuc cells with
EGF occurred over a time course that was similar to that of the activation of MAP kinase
by EGF (Figure 2.12, top left). MAP kinase is known to catalyze the phosphorylation of
the EGF receptor on Thr-669 (108, 109) and the phosphorylation of this residue on the
EGF receptor paralleled the activation of MAP kinase in EGFR-NLuc/CLuc cells (Figure
2.12, top left).
To determine whether the activation of MAP kinase played a role in the recovery
of luciferase complementation, EGFR-NLuc/CLuc cells were pre-treated with the MEK
inhibitor, U0126, to block the activation of MAP kinase. As shown in Figure 2.13, top
right, U0126 completely prevented both the activation of MAP kinase and the
phosphorylation of Thr-669. When cells were pretreated with U0126 prior to assay of
luciferase activity, U0126 had little effect on basal light production (Figure 2.12, bottom
left). However, this inhibitor completely blocked the recovery of luciferase activity after
the EGF-stimulated decrease (Figure 2.12, bottom right). The initial decrease was of a
greater magnitude than that seen in control cells and there was no recovery toward
baseline levels over the 20 min observation period. These data indicate that MAP kinase
activity is involved in the recovery phase of luciferase complementation.
The requirement for MAP kinase activation in the recovery of luciferase activity
was further examined using the T669A-EGF receptor. The T669A mutation removes the
MAP kinase phosphorylation site from the EGF receptor (108-110). The NLuc and CLuc
fragments were fused to the C-terminus of the T669A-EGF receptor and the constructs
were transiently transfected into CHO cells. As a control, wild type NLuc and CLuc
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EGF receptors were also transiently transfected into CHO cells. As shown in Figure
2.13A, the wild-type EGF receptor displayed basal luciferase activity which was
relatively stable over the 20 min time course of the experiment. Addition of EGF led to a
rapid decrease followed by a slow recovery of luciferase activity (Figure 2.13B). The
T669A-EGF receptor also displayed basal luciferase activity (Figure 2.13C). But in this
mutant, treatment with EGF led to a decrease in luciferase complementation with no
significant recovery back towards baseline levels of activity (Figure 2.13D).
Furthermore, the decrease observed in the T669A-EGFR-NLuc/CLuc cells was greater in
magnitude than that observed in the wild-type EGFR-NLuc/CLuc cells (Figure 2.13B and
D). This pattern was similar to that seen in cells expressing wild type EGFR-NLuc/CLuc
cells but treated with U0126 (Figure 2.12). These data suggest that the recovery in
luciferase complementation is a result of the phosphorylation of the EGF receptor on Thr669 by MAP kinase.
Discussion
The use of firefly luciferase for enzyme complementation has allowed continuous
monitoring of reversible conformational changes in the EGF receptor.

When the

luciferase fragments were fused to EGF receptors that contained only the extracellular
and transmembrane domains of the receptor, the system permitted the direct imaging of
EGF receptor dimerization in real time in living cells. The observed rate of receptor
dimerization paralleled the rate of ligand binding suggesting that the luciferase
complementation system responds rapidly to changes in proximity of the fragments,
allowing an accurate temporal read-out of receptor dimerization in vivo. Previous studies
that employed a ß-galactosidase complementation system reported dimerization rates that

29

were 5- to 10-fold slower than those observed here (111, 112). The time lag between
ligand binding and receptor dimerization, as measured by the ß-galactosidase assay, is
likely due to the fact that the ß-galactosidase assay must be performed ex vivo on lysed
cells and is susceptible to artifacts resulting from the slow, continuous accumulation of
product over time. Thus, the ß-galactosidase system is suboptimal for monitoring rapid
and dynamic changes in protein-protein interactions.
When the luciferase fragments were fused to the full-length EGF receptor,
substantially different results were obtained than with the truncated EGF receptor. A
significant basal luciferase activity was observed, suggesting that the unstimulated EGF
receptor exists in a conformation in which the C-terminal tails of the two monomers are
in close proximity to each other. This is consistent with previous reports that some
fraction of cell-surface EGF receptors exist as pre-formed dimers (42, 113-115).
Addition of the tyrosine kinase inhibitors erlotinib and AG1478 significantly increased
the basal luciferase activity. This is in agreement with the observation that the level of
inactive, pre-formed EGF receptor dimers is increased by treatment of cells with 4anilinoquinazoline tyrosine kinase inhibitors (116-119). Our finding that erlotinib also
enhanced basal luciferase complementation in the kinase-dead K721A-EGF receptor
system suggests that the effects of erlotinib are due solely to the binding of the inhibitor
and do not require an active tyrosine kinase.

Calmidazolium, an antagonist of

calmodulin, also led to a significant increase in the basal luciferase activity. While the
exact mechanism is not known, previous studies suggest that in addition to blocking
calmodulin activity, these types of inhibitors can also bind to the plasma and internal
membranes of the cell (105). This binding may change the electrostatic surface potential,
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disrupt EGF receptor interactions with the membrane in the basal state, and result in
enhanced accessibility of the luciferase fragments for one another (120).
Addition of EGF to the EGFR-NLuc/CLuc cells resulted in a biphasic response to
the ligand. Initially, EGF stimulated a rapid decrease in luciferase activity. This was
followed by a slower recovery back to baseline levels of luciferase complementation.
These findings are interpreted as the presence of two sequential, ligand-induced
conformational changes in the EGF receptor.
For several reasons, we do not feel that the observed changes are related to
internalization and/or degradation of the EGF receptor. First, the initial decrease in
luciferase activity occurs much more rapidly than the degradation of the EGF receptor.
Thus, it seems unlikely that the loss of luciferase activity is due to the loss of receptors.
Furthermore, the decrease in luciferase activity is reversible indicating that it cannot be
due to an irreversible process such as preoteolysis of the receptor. The recovery phase
could arise from clustering of the receptors in coated pits for internalization. However,
both U0126 treatment and the T669A mutation lead to enhanced receptor internalization
(121) and would thus be expected to promote the recovery phase. However, they actually
led to its ablation. It therefore seems probable that the observed changes in luciferase
activity are the result of conformational changes in the EGF receptor.
Treatment with EGF initially led to a rapid decrease in luciferase activity
consistent with the hypothesis that a conformational change had occurred that resulted in
the separation of the luciferase fragments.

The decrease in luciferase activity was

dependent on the concentration of EGF and reached its maximum 2 to 4 min after the
addition of EGF. This is well after receptor autophosphorylation has peaked, suggesting
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that this conformational change occurs as a result of receptor autophosphorylation rather
than concomitant with kinase activation.
Consistent with this hypothesis, treatment of the cells with erlotinib, AG1478,
TPA, or calmidazolium blocked the decrease in light production. More importantly,
mutation of the receptor to the kinase-dead K721A variant abolished the decrease in
luciferase activity and actually led to a system in which EGF stimulated an increase in
light production. This demonstrates that: i) the conformational dynamics reported by the
luciferase fragment complementation assay are the result of receptor tyrosine kinase
activity; and, ii) EGF does induce dimer formation in the context of the full-length EGF
receptor but its effects are masked by conformational changes within the intracellular
domain. The observation that tyrosine kinase inhibitors erlotinib and AG1478 blocked
the decrease in luciferase activity but did not reveal the increase in receptor dimer
formation in the wild type receptor may be due to the presence of residual kinase activity
in the inhibitor-treated cells. A low level of kinase activity would promote a decrease in
complementation thereby offsetting the increase in luciferase activity induced by EGF
receptor dimerization.
It is noteworthy that EGF stimulated dimerization of the kinase-dead EGF
receptor in the presence of erlotinib enhanced receptor-receptor interactions.

This

suggests that the effects of EGF and erlotinib on the formation of receptor dimers occur
through independent mechanisms.

Presumably, EGF induces dimerization of the

extracellular domains while erlotinib promotes kinase-kinase interactions within the
intracellular domain (58, 122-124). Whether these mechanisms can work additively
within the same receptor dimer (or tetramer) is unclear. However, the fact that EGF
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stimulated luciferase complementation in receptors that were fully saturated with
erlotinib suggests that this is likely the case.
The EGF receptor is extensively autophosphorylated on its C-terminal tail (55,
58-60) and previous studies on the isolated cytoplasmic domain of the receptor suggested
that the C-terminal tail adopts a more extended conformation following phosphorylation
(40, 41, 99). It was therefore possible that the decrease in luciferase activity was due to a
phosphorylation-induced change in the position of the C-terminal tails within the
activated EGF receptor dimer with no movement of the kinase domains. Fusion of the
luciferase fragments to a truncated EGF receptor lacking the C-terminal tail resulted in a
system in which both the initial decrease and the subsequent recovery of luciferase
complementation were visible but noticeably dampened.

This suggests that ligand

binding induces a change in the relative positions of the kinase domains that separates the
luciferase fragments. While changes in the C-terminal tails may also contribute to this
effect in the full-length receptor, the C-terminal tails seem to be relatively more important
in the recovery phase of luciferase complementation.
Luciferase fragment complementation identified a second ligand-induced
conformational change in the EGF receptor that followed the tyrosine phosphorylationdependent separation of the C-terminal tails. This second phase was marked by the
recovery of luciferase activity back to baseline levels. The recovery phase occurred over
a time course that was similar to the activation of MAP kinase, a downstream signaling
pathway stimulated by EGF. Inhibition of MAP kinase activation abolished the recovery
of luciferase activity suggesting that a MAP kinase-catalyzed phosphorylation event is
responsible for the increase in luciferase activity.
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MAP kinase is known to phosphorylate the EGF receptor on Thr-669 (108-110).
When the luciferase fragments were fused to the T669A-EGF receptor, EGF stimulated a
decrease in luciferase activity but the recovery phase was completely ablated. These data
are consistent with the interpretation that phosphorylation of the EGF receptor on Thr669 by MAP kinase induces a conformational change in the receptor that allows the reestablishment of complementation between the luciferase fragments.
Recent studies have demonstrated that phosphorylation of the EGF receptor on
Thr-669 leads to desensitization of the receptor (121).

Our data suggest that this

functional change in the EGF receptor is likely to be the result of a conformational
change in the receptor. We hypothesize that phosphorylation of the EGF receptor on
Thr-669 by MAP kinase induces a re-orientation of the kinase domains that results in the
adoption of a post-activated conformation of the receptor in which the C-terminal tails
are once again in close proximity. The relationship between the resting and the postactivated conformations of the receptor is not clear. However, because the activated
receptor would be phosphorylated, ubiquitinated and bound to a variety of interacting
molecules, it seems likely that the final conformation of the activated receptor would
differ substantially from that of an unstimulated receptor.
The data presented here are consistent with the model shown in Figure 2.14. A
significant basal photon flux was observed, indicating the presence of receptor-receptor
interactions in the inactive state (Figure 2.14A). Following addition of ligand, a rapid
decrease in luciferase activity was observed, indicating a separation of the luciferase
fragments (Figure 2.14B). This likely represents formation of the activating asymmetric
kinase dimer, which places the luciferase fragments in a position where they cannot
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complement. Finally, a recovery in luciferase activity to baseline levels was observed
that indicates the luciferase fragments can again complement (Figure 2.14C).

This

recovery was entirely dependent on the MAP kinase-mediated phosphorylation of the
EGF receptor on Thr-669, indicating that this modification alters the final conformation
adopted by the EGF receptor.
Li et al. (125) recently reported the use of luciferase fragment complementation to
study EGF receptor interactions. These workers reported that EGF did not elicit any
change in the photon flux in cells expressing NLuc and CLuc fused to the full-length
EGF receptor. However, their protocol involved treatment of their cells with EGF for 15
min prior to imaging. Thus, they only observed the system after it had recovered back to
baseline levels of luciferase complementation and failed to see the early dynamics that
follow ligand binding.
Our data demonstrate the utility of luciferase fragment complementation imaging
for monitoring reversible conformational changes in the EGF receptor in real time in
living cells. Utilizing this approach, we developed an assay for assessing dimerization of
the EGF receptor in intact cells using either C-terminally truncated or kinase-dead
receptors. This assay is superior to the chemical cross-linking studies normally used as it
is more sensitive and yields accurate information on the temporal progress of the
dimerization reaction.

The ability to generate temporal information allowed us to

identify two sequential ligand-induced changes in the conformation of the full-length
EGF receptor.

These observations reveal structural dynamics in the activated EGF

receptor and provide insight into how MAP kinase may induce desensitization of the
EGF receptor.
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Experimental Procedures
Reagents—Murine EGF was purchased from Biomedical Technologies, Inc. and
was dissolved in sterile water. U0126, AG1478, and calmidazolium were purchased
from EMD Chemicals and were dissolved in DMSO. Erlotinib was obtained from OSI
Pharmaceuticals and was dissolved in DMSO. 12-O-tetradecanoylphorbol 13-acetate
(TPA, Sigma) was dissolved in DMSO. Rapamycin was dissolved in DMSO and was
kindly provided by Dr. D. Piwnica-Worms (Washington University, St. Louis, MO).
Doxycycline was purchased from Clontech and was dissolved in sterile water.

D-

Luciferin (Biosynth) was dissolved in PBS and coelenterazine (Sigma) was dissolved in
ethanol. The MAP kinase antibody was from Upstate and the phospho-specific MAP
kinase and luciferase antibodies were from Promega. The phosphotyrosine antibody
(PY20) was from BD Biosciences. The phospho-Tyr1173 and phospho-Thr669 specific
antibodies were from Upstate. The EGF receptor was detected using Erbitux (ImClone)
or a mixture of antibodies from Cell Signaling and Santa Cruz.
DNA Constructs—To generate the EGFR-NLuc construct, Notch full-lengthNLuc (NFL-NLuc, kindly provided by Dr. R. Kopan Washington University, St. Louis,
MO) was digested with BsiWI and XbaI. A flexible Gly-Ser rich linker was generated
(amino acid sequence WPRSYASRGGGSSGGG) (100) containing SacII, BsiWI, and
XbaI sites. The linker was ligated into the NFL-NLuc construct using the BsiWI and
XbaI sites. An EGFR-GFP construct (126) was digested with SacII and XbaI and was
ligated into the NFL-NLuc construct to generate EGFR-NLuc in pcDNA3.1 TOPO
(Invitrogen). EGFR-NLuc was ligated into MCSI of the pBI-Tet vector (Clontech) using
the NheI and EcoRV sites.
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EGFR-CLuc was constructed by ligating NFL-CLuc (kindly provided by Dr. R.
Kopan Washington University, St. Louis, MO) into EGFR-NLuc using the HindIII and
BsiWI restriction sites. EGFR-CLuc was cloned into pcDNA6/V5-His B (Invitrogen)
using the BstEII and EcoRV sites in the EGFR pcDNA6/V5-His B construct. To make
the ΔC-EGFR-NLuc and CLuc constructs, a BsiWI site was inserted in the ΔC-EGFR
(127) (pBI-Tet) construct using QuikChange site-directed mutagenesis (Stratagene).
EGFR-NLuc (pBI-Tet) and EGFR-CLuc (pcDNA6/V5-His B) were digested with NheI
and BsiWI and ΔC-EGFR was ligated into these sites. This resulted in the following
linker DYKAYASRGGGSSGGG (100). To make the c′973-EGFR-NLuc and CLuc
constructs, a BsiWI site was inserted into the EGFR (pcDNA5.FRT) following amino
acid 973 using QuikChange site-directed mutagenesis. The DNA was digested with NheI
and BsiWI and cloned into the EGFR-CLuc (pcDNA6/V5-His B) or EGFR-NLuc (pBITet) constructs, resulting in the following linker YASRGGGSSGGG (100). The K721AEGFR-CLuc construct was made using QuikChange site-directed mutagenesis
(Stratagene) in the EGFR-CLuc pcDNA6/V5-His B construct. The K721A-EGFR-NLuc
construct was made by digesting EGFR-NLuc (pcDNA3.1 TOPO) with BstEII and KpnI.
The insert was ligated into the K721A pcDNA5.FRT (Invitrogen) construct digested with
the same enzymes. The T669A-EGFR-CLuc construct was made using QuikChange sitedirected mutagenesis (Stratagene) in the EGFR-CLuc pcDNA6/V5-His B construct. The
T669A-EGFR-NLuc construct was made by digesting EGFR-NLuc (pcDNA3.1 TOPO)
with BstEII and KpnI. The insert was ligated into the T669A pcDNA5.FRT (Invitrogen)
construct digested with the same enzymes. All mutations were verified by sequencing.
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The FRB-NLuc and CLuc-FKBP constructs were kindly provided by Dr. D.
Piwnica-Worms (100) (Washington University, St. Louis, MO).
Cell lines—CHO-K1 Tet-On cells (Clontech) were cotransfected with pTK-Hyg
(Clontech) and EGFR-NLuc (pBI-Tet MCSI) using Lipofectamine 2000 (Invitrogen).
Stable clones were isolated by selection in 400 µg/ml hygromycin (Invitrogen).

A

double-stable cell line was established by transfecting EGFR-CLuc (pcDNA6/V5-HisB)
into EGFR-NLuc cells using Lipofectamine 2000 and selecting in 10 µg/ml blasticidin-S
(Invitrogen). Double-stable lines were grown in DMEM containing 10% FBS, 1000
µg/ml penicillin/streptomycin, 100 µg/ml G418, 50 µg/ml hygromycin, and 2 µg/ml
blasticidin-S. ΔC-EGFR-NLuc (pBI-Tet MCSI) and c′973-EGFR-NLuc (pBI-Tet MCSI)
were stably expressed as described above for EGFR-NLuc. Cells were maintained in
DMEM containing 10% FBS, 1000µg/ml penicillin/streptomycin, 200µg/ml G418, and
100µg/ml hygromycin. ΔC-EGFR-CLuc (pcDNA6/V5-His B) and c′973-EGFR-CLuc
(pcDNA6/V5-His B) were transiently transfected into the appropriate parental cell line 24
hr prior to luciferase complementation imaging using Lipofectamine 2000 (Invitrogen).
The K721A-EGFR-NLuc/K721A-EGFR-CLuc constructs and the T669A-EGFRNLuc/T669A-EGFR-CLuc constructs were transiently transfected into CHO-K1 Tet-On
cells 24 hours prior to luciferase complementation imaging using Lipofectamine 2000.
To assess the transfection efficiency, cells were co-transfected with renilla luciferase
(pRLuc-N1, Packard Bioscience). FI CHO cells were purchased from Invitrogen and
were co-transfected with wild type EGFR (pcDNA5.FRT) and pOG44. Stable clones
were selected in F-12 media containing 10% FBS, 1000 µg/ml penicillin/streptomycin,
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and 400 µg/ml hygromycin. Cell lines were maintained in F-12 containing 100 µg/ml
hygromycin.
Kinase activation and Western Blotting—EGFR-NLuc/CLuc or FI CHO EGFR
cells were grown to confluence in 35 mm dishes. Cells were serum-starved in DMEM
containing 1 mg/ml BSA for 3 hr. Culture medium was removed and cells were washed
twice in ice-cold PBS and then scraped into RIPA buffer (150 mM NaCl, 10 mM Tris pH
7.2, 0.1% sodium dodecylsulfate, 1% Triton X-100, 17 mM deoxycholate, and 2.7 mM
EDTA) containing 20 mM p-nitrophenyl phosphate, 1 mM sodium orthovanadate, and
protease inhibitors. Equal amounts of protein (BCA assay, Pierce) were loaded onto a
9% SDS-polyacrylamide gel and then transferred to PVDF (Millipore) or nitrocellulose
(Osmonics, Inc.). Western blots were blocked for 1 hour in TBST/10% nonfat milk. The
blots were incubated in primary antibody for 1 hr, washed in TBST/0.1% BSA, incubated
in secondary antibody for 45 min and washed three times in TBST/0.1% BSA. Western
blots were detected using the ECL reagent from GE Healthcare.
125

I-EGF Binding—Murine EGF was radioiodinated and ligand binding assays

were performed as described previously (102).
Luciferase complementation imaging—Cells were plated 48 hr prior to use at 5
x103 cells per well in DMEM containing doxycycline in a black-walled 96-well plate.
On the day of the assay, cells were serum-starved for 3 hr and then incubated for 20 min
in 175 µl DMEM without phenol red, containing 1 mg/ml BSA, 25 mM Hepes, and 0.6
mg/ml D-luciferin at 37°C. To establish a baseline, cell radiance (photons/second/cm2/sr)
was measured using a cooled CCD camera and imaging system at 37°C (IVIS 50;
Caliper) (30 sec exposure; binning, 8; no filter; f-stop, 1; field of view, 12 cm). EGF was

39

added in a volume of 25 µl in the same media (DMEM, 1mg/ml BSA, 25mM Hepes,
0.6mg/ml D-Luciferin). Radiance was measured sequentially as described above. For
the ΔC-EGFR, c′973-EGFR, K721A-EGFR, and T669A-EGFR experiments involving
transient transfection, the transfection efficiency was assessed by monitoring renilla
luciferase expression.

Media was replaced on cells with DMEM (no phenol red)

containing 1 mg/ml BSA, 25 mM Hepes, and 400 nM coelenterazine. Radiance was
immediately measured as described above except the filter was set to <510.
Data Analysis—Data was collected in quadruplicate for each condition. A flatfield correction was done to correct for differences in the baseline photon flux. Light
production expressed as photon flux (photons/sec) was determined from regions-ofinterest defined over wells using LIVINGIMAGE (Xenogen) and IGOR (Wavemetrics)
software. Changes in photon flux were calculated by subtracting values from untreated
cells from those of EGF-treated cells. Standard errors were determined using the formula
for the unpooled standard error.
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Figure 2.1. Reconstitution of luciferase activity and 125I-EGF binding in ΔC-EGFRNLuc/CLuc CHO cells. ΔC-EGFR-NLuc CHO cells were plated 48 hr prior to imaging
in DMEM containing 1 µg/ml doxycycline. 24 hrs before imaging, cells were transiently
transfected with cDNA encoding ΔC-EGFR-CLuc. On the day of imaging, cells were
pre-incubated for 20 min with 0.6 mg/ml D-luciferin. A) Photon flux (photons/sec; p/s)
in the absence of agonist stimulation (open circles) or in the presence of 10 nM EGF
(closed squares). B) Change in photon flux over time in cells stimulated with 1 nM (open
circles, association rate 0.14 ± 0.015 min-1) or 10 nM (closed circles, association rate 0.30
± 0.03 min-1) EGF. C) Time course of 125I-EGF binding to cells expressing ΔC-EGFRNLuc at 37º C using 1 nM (open circles, association rate 0.15 ± 0.02 min-1) or 10 nM
(closed circles, association rate 0.42 ± 0.13 min-1) EGF. Error bars represent the standard
error of four independent measurements for each condition. The one-phase exponential
association was fit in B and C using non-linear least squares analysis with the GraphPad
Prism software.
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Figure 2.2. Characterization of the full-length EGFR-NLuc and EGFR-CLuc. A)
Scatchard analysis of 125I-EGF binding to CHO cells stably expressing EGFR-CLuc (no
doxycycline, open circles) or EGFR-NLuc/CLuc (closed circles) in which EGFR-NLuc
expression had been induced by the addition of 1 µg/ml doxycycline for 48 hrs. Data
were fit to a two-site binding hyberbola using nonlinear regression from the GraphPad
Prism software. B) CHO cells stably expressing either EGFR-NLuc or EGFR-CLuc were
stimulated with 10 nM EGF at 37ºC for the indicated lengths of time. Western blot
analysis was performed with the indicated antibodies. C) CHO cells stably expressing
either EGFR-NLuc (1µg/ml doxycycline for 48 hrs) or EGFR-CLuc were lysed and
Western plot analysis was performed with an anti-luciferase antibody.
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Figure 2.3. Reconstitution of luciferase activity in response to EGF in EGFRNLuc/CLuc cells. EGFR-NLuc/CLuc cells were plated into DMEM containing 1 µg/ml
doxycycline 48 hr prior to imaging. Before collecting data, cells were incubated for 20
min with 0.6 mg/ml D-luciferin. A) Photon flux (photons/sec; p/s) in the absence of
ligand. B-G) Change in photon flux following addition of varying concentrations of
EGF. H) HeLa cells were plated 48 hrs prior to bioluminescence imaging in DMEM.
Cells were transiently transfected with FRB-NLuc and CLuc-FKBP (100) 24 hrs prior to
imaging. Cells were pre-treated with rapamycin (80 nM for 5 hrs). Before collecting
data, cells were incubated for 20 min with 0.6 mg/ml D-luciferin. Photon flux was
immediately measured over time after the addition of vehicle, 10 nM EGF, or rapamycin.
Error bars represent the standard error of four independent measurements for each
condition.
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Figure 2.4. Competition of basal luciferase complementation using unlabeled wild
type EGF receptor. EGFR-NLuc/CLuc cells were plated in DMEM containing 1µg/ml
doxycycline 48 hrs prior to imaging. Cells were transiently transfected with empty vector
(pcDNA5.FRT) or unlabeled wild type EGF receptor 24 hrs prior to imaging. Before
collecting data, cells were serum starved for 3 hrs and then were incubated for 20 min in
0.6 mg/ml D-luciferin. The maximum photon flux (photons/sec; p/s) is shown for several
concentrations of wild type unlabeled EGF receptor or after cells were stimulated with 10
nM EGF.

Figure 2.5. Comparison of the rate of EGF receptor autophosphorylation to the
EGF-stimulated decrease in luciferase activity.
For the EGF receptor
autophosphorylation, EGFR-NLuc/CLuc cells were plated in 6-well dishes in DMEM
containing 1 µg/ml doxycycline 48 hrs prior to assay. On the day of assay, cells were
serum starved for 3 hrs before stimulation with 10 nM EGF for the indicated lengths of
time. Cells were lysed and equal proteins were loaded on a 9% SDS-PAGE gel. Proteins
were transferred and Western blot analysis was done with a phosphotyrosine antibody
(pY20, BD Biosciences). Densiometric analysis was done using Image J (NIH). For
luciferase imaging, EGFR-NLuc/CLuc cells were plated in DMEM containing 1 µg/ml
doxycycline 48 hrs prior to imaging. Before collecting data, cells were incubated for 20
min with 0.6 mg/ml D-Luciferin. Photon flux (photons/sec; p/s) was measured after
addition of 10 nM EGF. Error bars represent the standard error of four independent
measurements for each condition.
44

Figure 2.6. Inhibition of EGF receptor autophosphorylation and MAP kinase
activation following pre-treatment with AG1478 or Erlotinib. FI CHO cells stably
expressing the EGF receptor were plated 48 hrs prior to assay in 6-well dishes. On the
day of the assay, cells were serum starved 3 hrs. Cells were pre-treated with the indicated
concentrations of AG1478 for 20 min or with erlotinib for 1 hr. 25 nM EGF was added
for 3 min, cells were lysed, and equal proteins were loaded on a 9% SDS-PAGE gel.
Western blot analysis was done with the indicated antibodies.
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Figure 2.7. Effect of a kinase inhibitor on reconstituted luciferase activity. A)
EGFR-NLuc/CLuc cells were plated in DMEM containing 1 µg/ml doxycycline 48 hrs
prior to imaging. EGFR-NLuc/CLuc CHO cells were treated with vehicle or 5 µM
erlotinib for 1 hr prior to imaging. Cells were treated for 20 min with 0.6 mg/ml DLuciferin prior to imaging. A) Basal luciferase activity in photon flux (photons/sec; p/s).
Control values were corrected independently by the baseline for erlotinib or AG1478. B)
HeLa cells were plated 48 hrs prior to bioluminescence imaging in DMEM. Cells were
transiently transfected with FRB-NLuc and CLuc-FKBP (100) 24 hrs prior to imaging.
Cells were pre-treated with rapamycin (80 nM for 5 hrs). Before collecting data, cells
were incubated for 20 min with 0.6 mg/ml D-luciferin. Photon flux was immediately
measured over time after the addition of vehicle, 5 µM erlotinib, 10 µM AG1478, or
rapamycin. The control in this experiment is also used in Figure 2.3H. C and D)
Luciferase activity in EGFR-NLuc/CLuc cells as in (A) treated with 10 nM EGF in the
absence or presence of 10 µM AG1478 (C) or 5 µM erlotinib (D) pre-treatment. Error
bars represent the standard error of four independent measurements for each condition.
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Figure 2.8. Effect of TPA treatment on EGF receptor autophosphorylation and
luciferase activity in EGFR-NLuc/CLuc cells. EGFR-NLuc/CLuc cells were plated in
DMEM containing 1µg/ml doxycycline 48 hrs prior to assay or imaging. Cells were
serum starved 3 hrs on the day of assay, followed by pre-treatment for 20 min in vehicle
or 100 nM TPA. A) Cells were stimulated with 10 nM EGF for the indicated lengths of
time and were then lysed. Equal proteins were loaded on a 9% SDS-PAGE gel and
Western blot analysis was done with the indicated antibodies. B and C) Prior to
luciferase complementation imaging, cells were incubated for 20 min in DMEM
containing 0.6 mg/ml D-luciferin and DMSO (vehicle) or 100 nM TPA. Photon flux
(photons/sec; p/s) was immediately measured after addition of vehicle (B) or 10 nM EGF
(C).
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Figure 2.9. Effect of the protein kinase C activator, calmidazolium, on EGF
receptor autophosphorylation and reconstituted luciferase activity.
EGFRNLuc/CLuc or HeLa cells were plated in DMEM containing 1µg/ml doxycycline 48 hrs
prior to assay or imaging. Cells were serum starved 3 hrs on the day of assay, followed
by pre-treatment for 20 min in vehicle or 10 µM calmidazolium. A) Cells were stimulated
with 10 nM EGF for the indicated lengths of time. Cells were lysed, equal proteins were
loaded on a 9% SDS-PAGE gel and Western blot analysis was done with the indicated
antibodies. B) Prior to luciferase complementation imaging, cells were incubated for 20
min in DMEM containing 0.6 mg/ml D-luciferin and DMSO (vehicle) or 10 µM
calmidazolium. Photon flux (photons/sec; p/s) was immediately measured. Control
values were corrected independently by the baseline for calmidazolium. C) He La cells
were transiently transfected with FRB-NLuc and CLuc-FKBP (100) 24 hrs prior to
imaging. Cells were pre-treated with rapamycin (80 nM for 5 hrs). Before collecting
data, cells were incubated for 20 min with 0.6 mg/ml D-luciferin. Photon flux was
immediately measured over time after the addition of vehicle, 10 µM calmidazolium, or
rapamycin. The control in this experiment is also used in Figure 2.3H. D) EGFRNLuc/CLuc cells were treated as in (B) except that photon flux was measured after
addition of 10 nM EGF. Error bars represent the standard error of at least four
independent measurements.
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Figure 2.10.
Expression of kinase-dead EGF receptor and the effect on
reconstituted luciferase activity. CHO-K1 Tet-On cells were plated in DMEM 48 hrs
prior to luciferase imaging. Cells were transiently transfected with cDNA for K721AEGFR-NLuc and K721A-EGFR-CLuc 24 hrs prior to imaging. Prior to imaging, cells
were serum starved 2 hrs, pre-treated for 1 hr in media containing vehicle or 5 µM
erlotinib, and then treated for 20 min with 0.6 mg/ml D-Luciferin. A) Basal photon flux
(photons/sec; p/s). Control values were corrected independently by the baseline for
erlotinib. B) Luciferase activity in cells treated with 10 nM EGF. Error bars represent
the standard error of four independent measurements for each condition.

Figure 2.11. Effect of truncation of the C-terminal tail of the EGF receptor on
reconstituted luciferase activity. CHO cells stably expressing c′973-EGFR-NLuc were
plated in DMEM containing 2 µg/ml doxycycline 48 hrs prior to luciferase imaging.
Cells were transiently transfected with c′973-EGFR-CLuc 24 hrs prior to imaging. Cells
were treated for 20 min with 0.6 mg/ml D-Luciferin prior to imaging. A) Basal photon
flux (photons/sec; p/s). B) Luciferase activity in cells treated with 10 nM EGF. Error
bars represent the standard error of four independent measurements for each condition.
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Figure 2.12. Contribution of MAP kinase activation to the recovery of reconstituted
luciferase activity. EGFR-NLuc/CLuc cells were plated 48 hrs prior to assay in DMEM
containing 1 µg/ml doxycycline. Cells were serum starved for 3 hrs prior to assay.
EGFR-NLuc/CLuc cells were pre-treated with vehicle (control, top left) or 10 µM U0126
(top right) for 20 min prior to addition of 10 nM EGF at time = 0. Western blot analysis
was performed with the indicated antibodies. For the luciferase imaging, EGFRNLuc/CLuc cells were plated 48 hrs before imaging in DMEM containing 1 µg/ml
doxycycline. EGFR-NLuc/CLuc cells were pre-treated with vehicle (control) or 10 µM
U0126 for 20 min (both in the presence of 0.6 mg/ml D-Luciferin). The photon flux in
the absence of ligand (bottom left) or after addition of 10 nM EGF (bottom right) was
monitored over time. Error bars represent the standard error of four independent
measurements for each condition.
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Figure 2.13. Effect of mutation of Thr-669 of the EGF receptor on reconstituted
luciferase activity. Panels A-B) CHO-K1 Tet-On cells were transiently transfected with
EGFR-NLuc and EGFR-CLuc 24 hrs prior to imaging. Cells were treated for 20 min
with 0.6 mg/ml D-Luciferin prior to imaging. A) Basal photon flux (photons/sec; p/s).
B) Luciferase activity in cells treated with 10 nM EGF. Panels C-D) CHO-K1 Tet-On
cells were transiently transfected with T669A-EGFR-NLuc and T669A-EGFR-CLuc 24
hrs prior to imaging. Cells were treated for 20 min with 0.6 mg/ml D-Luciferin prior to
imaging. C) Photon flux (photons/sec; p/s) in the absence of ligand. D) Change in
photon flux following addition of 10 nM EGF. Error bars represent the standard error of
four independent measurements for each condition.
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Figure 2.14. Model for intracellular domain conformational changes observed using
luciferase fragment complementation imaging of the full-length EGF receptor. A)
In the absence of ligand, a significant photon flux is observed, indicating the presence of
basal receptor-receptor interactions. B) Addition of ligand induces formation of the
activating asymmetric EGF receptor kinase dimer. Transition to this conformational state
separates the luciferase fragments, placing them in a conformation where interaction is no
longer possible, resulting in the observed decrease in luciferase activity. C) Following
the ligand-induced decrease in luciferase activity, a recovery is observed that is
dependent on MAP kinase activity and the presence of an intact EGF receptor Thr-669
that can be phosphorylated. White circles represent unphosphorylated residues, while red
circles indicate the presence of phopshorylation.
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CHAPTER 3. MAP Kinase Desensitizes the EGF Receptor by Blocking Allosteric
Activation of the Kinase Domain
Introduction
Following activation, the EGF receptor is desensitized in order to dampen
receptor signaling.

Long-term desensitization is mediated by internalization and

degradation of the receptor (82, 83). In addition, there exists a more rapid desensitization
mechanism thought to be mediated by a reduction in protein tyrosine kinase activity (8688). More specifically, previous work suggests that this rapid desensitization mechanism
relies on phosphorylation of the EGF receptor on two threonine residues (Thr-654 and
Thr-669) within the intracellular juxtamembrane region (93, 94). Of these two sites, Thr669 is the major site of threonine phosphorylation in the EGF receptor (95).
Phosphorylation of this site is mediated by a feedback loop: the EGF receptor activates
MAP kinase, which in turn directly phosphorylates the EGF receptor on Thr-669 (96-98).
Mutation of Thr-669 to Ala is associated with enhanced EGF receptor phosphorylation
(94).

Despite recognition that phosphorylation of Thr-669 is associated with EGF

receptor desensitization, the mechanism by which phosphorylated Thr-669 blocks
receptor kinase activity is not understood.
Recent studies by two groups highlights the importance of the intracellular
juxtamembrane region in activation of the EGF receptor kinase domain (36, 38, 39).
These studies were discussed in detail earlier and so will not be repeated here. The
important finding of these studies was that activation of the EGF receptor kinase domain,
through formation of the asymmetric dimer, relies on additional contacts mediated by the
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intracellular juxtamembrane domain of the acceptor kinase and the C-lobe of the donor
kinase.
In Chapter 2, luciferase fragment complementation imaging identified sequential
ligand-induced conformational changes in the EGF receptor. The final conformation
adopted by the EGF receptor was dependent on MAP kinase activation. The time course
of this conformational change followed the time course of activation of MAP kinase and
EGF receptor Thr-669 phosphorylation. These data suggested that desensitization of the
EGF receptor through phosphorylation on Thr-669 may result in a re-orientation of the
kinase domains that leads to a loss in tyrosine kinase activity.
The aim of this chapter is to describe mechanistically how MAP kinase mediates
desensitization of the EGF receptor. Acidic residues were identified in the C-lobe of the
donor kinase domain that are in proximity to Thr-669 of the activator kinase domain. We
hypothesized that when Thr-669 is phosphorylated by MAP kinase, a charge repulsion
exists that blocks the allosteric activation mechanism of the kinase domain, resulting in a
loss of tyrosine kinase activity. Mutations in the kinase domain of either Thr-669 or Clobe acidic residues to alanines resulted in an enhancement of EGF receptor
autphosphorylation and reduced sensitivity to MAP kinase activation compared to the
wild type receptor. Luciferase fragment complementation imaging of these mutants
showed that upon EGF stimulation, there was an initial rapid decrease in luciferase
activity similar to the wild type receptor. However, the subsequent recovery of luciferase
activity observed in wild type receptor was completely ablated.
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Results
EGF induces enhanced phosphorylation and internalization of the T669A-EGF receptor
MAP kinase has been shown to phosphorylate the EGF receptor on Thr-669 (97,
98). As shown in Figure 3.1A, treatment of cells expressing the wild type EGF receptor
with

EGF

leads

to

a

dose-dependent

increase

in

the

level

of

receptor

autophosphorylation. This is associated with the activation of MAP kinase and the
concomitant phosphorylation of the EGF receptor on Thr-669.
MAP kinase is also activated in response to EGF in cells expressing the T669AEGF receptor (Figure 3.1A). As expected, there is no phosphorylation of this receptor on
Thr-669.

However, there is a clear increase in the level of EGF receptor

autophosphorylation as compared to that seen in the wild type EGF receptor. These data
are consistent with previous reports (94) and suggest that phosphorylation of the EGF
receptor on Thr-669 leads to a desensitization of the tyrosine kinase activity of the EGF
receptor.
The ability of the T669A-EGF receptor to mediate internalization of 125I-EGF was
next examined. Cells were incubated at 37°C with 1 nM 125I-EGF for varying lengths of
time. The amount of internalized

125

I-EGF/surface

125

I-EGF was plotted versus the

length of incubation time to determine the internalization rate (Figure 3.1B). Both the
wild-type and T669A-EGF receptors mediated internalization of EGF, however, the rate
of internalization of the T669A-EGF receptor was faster compared to the wild-type EGF
receptor (0.078 ± 0.004 min-1 versus 0.052 ± 0.003 min-1, respectively).

This is

consistent with the observation that the T669A-EGF receptor has increased
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autophosphorylation compared to the wild-type EGF receptor and is therefore likely to
internalize at an increased rate.
Mutation of acidic amino acids in the C-lobe of the EGF receptor kinase domain result in
elevated autophosphoryatlion independent of MAP kinase activity
Thr-669 is in the intracellular juxtamembrane domain of the EGF receptor, just
upstream of the tyrosine kinase domain (Figure 3.2). Several recent studies (36, 38, 39)
have shown that the juxtamembrane domain participates in the activation of the tyrosine
kinase. In particular, the juxtamembrane domain of the acceptor kinase interacts with the
C-lobe of the donor kinase to stabilize the asymmetric dimer interface. Phosphorylation
of Thr-669 could desensitize the EGF receptor kinase by destabilizing the activating
asymmetric dimer interface.
Examination of the asymmetric dimer formed by a recent EGF receptor kinase
domain structure (39) as well as that of the homologous ErbB4 kinase (37) showed that
Thr-669 lies in close proximity to several acidic amino acids (Asp-950, Asp-960 and Glu961) in the C-lobe of the donor kinase (Figure 3.2). The unphosphorylated Thr-669 could
interact favorably with these residues. When a kinase with a phosphorylated Thr-669
attempts to adopt the acceptor position, the highly negatively-charged phosphate group
would lead to charge repulsion and would preclude formation of the activating
asymmetric dimer.
To determine whether Asp-950, Asp-960 and/or Glu-961 were involved in the
mechanism of MAP kinase-dependent desensitization of the EGF receptor, these residues
were mutated to alanine and their effect on EGF receptor autophosphorylation assessed.
EGF

receptors

with

a

single-point

mutation
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(D950A),

a

double

mutation

(D960A/E961A), or a triple mutation (D950A/D960A/E961A) to the acidic residues were
stably expressed in cells. The results of these studies are shown in Figures 3.3-3.6.
Figure 3.3A compares the dose response to EGF in cells expressing the wild type
EGF receptor, the T669A-EGF receptor and the D960A/E961A-EGF receptor. While
EGF stimulated the phosphorylation of the receptor in all cell lines, autophosphorylation
of the EGF receptor was substantially higher in cells expressing the T669A- and
D960A/E961A-EGF receptors.
To determine whether the difference in the level of EGF receptor
autophosphorylation in the wild type as compared to the D960A/E961A-EGF receptors
was related to the phosphorylation of the receptor by MAP kinase, cells were treated
without or with the MEK inhibitor, U0126, prior to stimulation by EGF. As shown in
Figure 3.3B, treatment of all three cell lines with EGF led to the activation of MAP
kinase and this was completely blocked by pretreatment with U0126. In the wild type
EGF receptor, stimulation with EGF resulted in receptor autophosphorylation as well as
phosphorylation of the receptor on Thr-669.

Pretreatment with U0126 abolished

phosphorylation of the receptor on Thr-669 and was associated with an increase in EGF
receptor autophosphorylation. Due to the absence of the MAP kinase phosphorylation
site, the T669A-EGF receptor was not phosphorylated at residue 669 in either the absence
or presence of U0126.

Consistent with the lack of phosphorylation at this site,

pretreatment of these cells with U0126 did not alter the level of EGF receptor
autophosphorylation in the T669A-EGF receptor-expressing cells.
In contrast to the T669A-EGF receptor, the D960A/E961A-EGF receptor was
extensively phosphorylated at Thr-669 and this was abolished by pretreatment with
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U0126. Despite the major change in the level of Thr-669 phosphorylation, there was
only a modest increase in the level of EGF receptor autophosphorylation. These data
suggest that like the T669A mutation, the D960A/E961A mutation suppresses the effect
of MAP kinase phosphorylation on the activity of the EGF receptor.
The wild type EGF receptor exhibited enhanced autophosphoryaltion when MAP
kinase activation was blocked. However, the increase in autophosphorylation did not
reach the level of autophosphorylation observed in the T669A-EGF receptor (Figure
3.3B), suggesting possible alternative mechanisms of wild type EGF receptor
desensitization. To determine if similar levels of autophosphorylation could be observed
in the wild type EGF receptor as compared to the T669A-EGF receptor in the absence of
MAP kinase activation, we examined the autophosphorylation after stimulation with
higher concentrations of ligand. As shown in Figure 3.4, when the EGF receptor was
pre-treated with U0126 and then stimulated with 10 nM, as opposed to 1 nM EGF, an
additional increase in autphosphorylation was observed.
As shown previously and in Figure 3.4, the autophosphorylation of the T669AEGF receptor was higher than the wild type receptor when MAP kinase was active.
However, when MAP kinase activation was blocked, the levels of autophosphorylation
between the wild type and T669A-EGF receptor were indistinguishable after stimulation
with 10 nM, but not 1 nM EGF (Figure 3.4). This is similar to the results observed by Li
et al. when wild type and T669A-EGF receptors were stimulated with 1 nM EGF for
longer lengths of time (94). These results suggest a possible shift of ligand-induced
activation for the T669A-EGF receptor compared to the wild type EGF receptor.
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T669R-,

T669E-,

and

T669D-EGF

receptor

mutants

display

enhanced

autophosphorylation
Mutation of Thr-669 to Ala appears to block the MAP kinase-mediated
desensitization mechanism of the EGF receptor.

To further test this hypothesis,

additional mutations to the Thr-669 site were constructed. First, Thr-669 was mutated to
Arg, which would eliminate any charge repulsion with the acidic amino acids in the Clobe of the donor kinase. Thr-669 was also mutated to Asp and Glu to attempt to mimic
the effects of phosphorylation at this site.
Figure 3.5 compares the dose-response to EGF in cells expressing the wild type,
T669A-, T669R-, T669D-, and T669E-EGF receptors.

Addition of EGF to cells

expressing the wild type EGF receptor resulted in a dose-dependent increase in
autophosphorylation,

MAP

kinase

activation,

and

EGF

receptor

Thr-669

phosphorylation. Similar to the results in Figures 3.1 and 3.3, the T669A-EGF receptor
exhibited enhanced EGF receptor autophosphorylation and an absence of Thr-669
phosphorylation (Figure 3.5A). When the T669R-EGF receptor was expressed in CHO
cells, addition of EGF resulted in enhanced autophosphorylation compared to both the
wild type and T669A-EGF receptors, despite similar levels of receptor expression (Figure
3.5A). These data are consistent with MAP kinase desensitizing the EGF receptor by
establishing a charge repulsion that makes formation of the asymmetric dimer interface
unfavorable.
Similar to the other Thr-669 mutations, when the T669D-EGF receptors and
T669E-EGF receptors were expressed in CHO cells and stimulated with EGF, an increase
in autophosphorylation was observed compared to the wild type EGF receptor (Figure
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3.5B). Consistent with mutation of the Thr-669 phosphorylation site, the T669D- and
T669E-EGF receptors did not react with the phospho-Thr-669 antibody, while the wild
type EGF receptor did. Mutation of Thr-669 to an acidic residue was expected to lead to
decreased autophosphorylation by mimicking the presence of Thr-669 phosphorylation.
Instead an increase in autophosphorylation was observed that may reflect an inability of
these amino acids to mimic a phosphorylated amino acid.
Asp-950 is important in stabilizing the asymmetric kinase domain interface
Figure 3.6A compares the dose response to EGF in cells expressing the wild type,
D950A-, or D950A/D960A/E961A- triple mutant EGF receptors. Substitution of Asp950 with alanine markedly impaired the ability of EGF to stimulate autophosphorylation
of the D950A-EGF receptor. This result is consistent with Jura et al. who have recently
reported that mutation of Asp-950 to Ala leads to impaired EGF receptor
autophosphorylation (38).

This inhibition was largely overcome when the D950A

mutation was combined with the D960A/E961A mutation in the triple mutant, resulting
in autophosphorylation levels near the wild type EGF receptor.
The decrease in receptor autophosphorylation seen in the D950A-EGF receptor
suggests that Asp-950 may actually serve to stabilize the asymmetric dimer interface and
that its mutation destabilizes this interface.

Inspection of the EGF receptor kinase

domain structure (39) suggests that Asp-950 of the donor kinase could form a potential
hydrogen bond with Ser-671 in the juxtamembrane domain of the acceptor kinase. If so,
the D950A-EGF receptor mutant would exhibit decreased activity because of its
compromised ability to serve as a donor kinase. However, it could still serve as an
acceptor kinase since its N-lobe is intact.
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To test this hypothesis, the D950A-EGF receptor was expressed alone or in
combination with the L680N-EGF receptor. The L680N mutation is in the N-lobe of the
kinase domain and it blocks the ability of this receptor to serve as an acceptor kinase
(35). However, the receptor can still serve as a donor kinase. As shown in Figure 3.6B,
when expressed alone, the EGF-stimulated autophosphorylation of the D950A-EGF
receptor was low. Likewise, when expressed alone, the L680N-EGF receptor did not
undergo significant autophosphorylation. However, when the D950A-EGF receptor and
the L680N-EGF receptor were expressed together, EGF stimulated a marked increase in
the autophosphorylation of the EGF receptor. This is consistent with the interpretation
that the L680N-EGF receptor served as the donor kinase to activate the D950A-EGF
receptor.
Autophosphorylation is recovered in cells expressing the triple EGF receptor mutant,
D950A/D960A/E961A
The recovery in receptor autophosphorylation in the D950A/D960A/E961A-EGF
receptor suggests that mutation of Asp-950 to Ala is destabilizing, but mutation of Asp960/Glu-961 to Ala enables re-stabilization of the asymmetric dimer interface.

To

determine if this recovery is dependent on the MAP kinase-mediated effects through
phosphorylation on Thr-669, a double-mutant was established in which both Thr-669 and
Asp-950 were mutated to Ala (T669A/D950A-EGF receptor).

Addition of varying

concentrations of EGF resulted in a dose-dependent increase in autophosphorylation in
cells expressing the wild type EGF receptor (Figure 3.7). However, autophosphorylation
was still severely impaired in the T669A/D950A EGF receptor double-mutant,
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suggesting the recovery observed in the D950A/D960A/E961A-EGF receptor mutant is
independent of the effects of MAP kinase phosphorylation on Thr-669.
Asp-960 and Glu-961 are required to observe a recovery in luciferase activity
As described in Chapter 2, firefly luciferase can be divided into an N-terminal
fragment (NLuc) and a C-terminal fragment (CLuc), each of which are inactive (100,
101). However, when brought into proximity, the two fragments complement each other,
producing an active luciferase enzyme. Thus, luciferase fragment complementation can
be used to detect the proximity of two molecules tagged with the different luciferase
fragments.

These studies can be done in real time in intact cells which allows for

continuous imaging of changes in the proximity or conformation of the tagged protein.
Chapter 2 demonstrated that when the NLuc and CLuc fragments were fused to
the carboxy-terminus of the full length EGF receptor this system could be used to image
conformational changes in the EGF receptor that occur in response to EGF (128). Figure
3.8A and B show the results of such a control experiment using the wild type EGF
receptor. As previously reported, significant luciferase activity was observed in the
absence of EGF indicating the presence of pre-formed dimers (Figure 3.8A). Upon
addition of 10 nM EGF (Figure 3.8B), there was a rapid decrease in luciferase activity
followed by a somewhat slower recovery back to baseline levels. The results in Chapter
2 demonstrated that the initial decline in luciferase complementation occurs as a
consequence of the autophosphorylation of the EGF receptor while the recovery phase is
a result of the phosphorylation of the EGF receptor on Thr-669 by MAP kinase.
These data are recapitulated in Figure 3.8C and D which show luciferase fragment
complementation in the T669A-EGF receptor mutant. Like the wild type receptor, the
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T669A-EGF receptor showed substantial basal luciferase activity (Figure 3.8C). Also
like the wild type receptor, addition of EGF induced a rapid decrease in luciferase
activity (Figure 3.8D). However, the subsequent recovery phase was absent in sharp
contrast to wild type EGF receptor. Luciferase activity reached a lower plateau and
remains that way for the duration of the experiment. This was due to the loss of the MAP
kinase phosphorylation site in the T669A-EGF receptor.
As can be seen in Figures 3.8E and F, luciferase fragment complementation in the
D960A/E961A-EGF receptor exhibited the same pattern as that seen in the T669A-EGF
receptor—EGF stimulated a rapid decline in luciferase activity with no recovery. These
data indicate that the D960A/E961A-EGF receptor does not undergo the MAP kinasedependent conformational change that gives rise to the recovery phase in luciferase
fragment complementation. Thus, the data confirm that this mutant is insensitive to the
effects of MAP kinase phosphorylation.
Mutation of Asp-950 leads to a rapid increase in luciferase activity
The pattern of luciferase fragment complementation is different in cells
expressing the K721A-kinase-dead EGF receptor (Figure 3.9A and B). In this case, there
is no decrease in luciferase complementation because this initial decline requires
autophosphorylation of the receptor (Chapter 2, Figures 2.7-2.9). Instead, there is an
increase due to enhanced dimerization of the receptor mediated by the extracellular
domains.

The pattern of luciferase fragment complementation in the D950A-EGF

receptor is similar to that seen in the K721A-EGF receptor, consistent with its severely
compromised kinase activity (Figure 3.9C and D).
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Discussion
Expression of an EGF receptor mutant lacking the MAP kinase phosphorylation
site, T669A-EGF receptor, led to enhanced autophosphorylation and internalization
compared to the wild type receptor. Li et al. observed a similar increase in EGF receptor
autophosphorylation and degradation using the same mutation (94). This is consistent
with a role for this residue in the rapid MAP kinase-mediated desensitization mechanism.
In Chapter 2, luciferase complementation imaging of cells pre-treated with an
inhibitor to block MAP kinase activation or of cells expressing the T669A mutation
displayed a decrease but no recovery in luciferase activity (Figures 2.12 and 2.13). These
results were interpreted as MAP kinase phosphorylation on the EGF receptor at Thr-669
being critical for the final conformation adopted by the EGF receptor. In this Chapter,
the goal was to understand mechanistically how MAP kinase desensitization alters the
conformational state of the EGF receptor.
Recent crystal structures of the EGF receptor provided structural insight into the
potential mechanism for MAP kinase-mediated EGF receptor desensitization. These
crystal structures reveal the location of Thr-669, which lies in the intracellular
juxtamembrane region, between the transmembrane and kinase domains (37, 39).
Inspection of these crystal structures indicated a region of negatively charged amino acids
(Asp-950, Asp-960, and Glu-961) in the C-lobe of the donor kinase (Figure 3.2) that
could unfavorably interact with a phosphorylated Thr-669, leading to an inability to form
the activating asymmetric dimer and hence a desensitization of EGF receptor kinase
activity.
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When Asp-960 and Glu-961 were both mutated to Ala (D960A/E961A-EGF
receptor), enhanced autophosphorylation was observed compared to the wild type EGF
receptor, indicating a loss of desensitization. Pre-treatment of cells with a MEK inhibitor
to block MAP kinase activation resulted in an increase in wild type EGF receptor
autophosphorylation, indicating a loss of receptor desensitization. In contrast, T669Aand D960A/E961A-EGF receptor mutants were insensitive to the MEK inhibitor,
suggesting that the receptors already lacked the desensitization mechanism. Li et al.
showed similar results with the wild type and T669A-EGF receptor using a different
MEK inhibitor (94).
The

D960A/E961A-EGF

receptor

did

show

a

small

increase

in

autophosphorylation in the presence of the inhibitor to block MAP kinase activation,
albeit this increase was significantly less than that observed for the wild type EGF
receptor under identical conditions. This small increase may reflect the involvement of
additional residues in the MAP kinase-mediated EGF receptor desensitization.
Because

the

D960A/E961A-EGF

receptor

mutant

exhibited

increased

autophosphorylation in comparison to the T669A-EGF receptor, it is possible that in
addition to desensitization, these residues are important for additional regulatory
mechanisms. Both Asp-960 and Glu-961 are located at the junction between the EGF
receptor kinase domain and C-terminal tail. Further inspection of crystal structures of the
EGF receptor kinase domain C-lobe indicate that Asp-960 may form an intramolecular
hydrogen-bond to Ser-787 (35, 37-39, 129-131). Thus, Asp-960 may not function in
MAP kinase-mediated desensitization; rather it may function as a pivot point for
movement of the C-terminal tail while it undergoes autophosphorylation.
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A recent study by Jura et al. determined a crystal structure of the EGF receptor
kinase domain with a longer portion of the C-terminal tail than was previously observed
(amino acids 960-990) (38). The position of the C-terminal tail suggests that it may be
autoinhibitory and requires displacement by the intracellular juxtamembrane domain
during formation of the asymmetric dimer. Because Asp-960 is located at the junction of
the kinase and C-terminal tail domains, it may be the pivot point for this displacement.
Mutation of Asp-960 so it can no longer hydrogen-bond with Ser-787 would facilitate
displacement of the C-terminal tail, possibly leading to enhanced EGF receptor
autophosphorylation. If this is the case, then the D960A/E961A-EGF receptor double
mutant would exhibit enhanced autophosphorylation compared to the wild type EGF
receptor and the T669A-EGF receptor for two reasons: 1) an inability to undergo MAP
kinase-mediated desensitization through charge repulsion between phospho-Thr-669 and
Glu-961, and 2) facilitated displacement of the C-terminal tail due to mutation of the
Asp-960/Ser-787 hydrogen-bond. The dual effects of the D960A/E961A-EGF receptor
would explain why autophosphorylation is enhanced compared to the T669A-EGF
receptor and why the wild type EGF receptor with desensitization blocked cannot attain
autophosphorylation levels comparable to the D960A/E961A-EGF receptor.
Luciferase complementation imaging of the full-length EGF receptor captured a
series of ligand-induced conformational changes by the intracellular domain (Chapter 2,
Figure 2.3). The final conformation adopted by the EGF receptor was shown to be
dependent on MAP kinase activity because blocking MAP kinase activation completely
abolished the recovery in luciferase activity (Figure 2.12). Additionally, mutation of the
Thr-669 phosphorylation site eliminated the recovery but not the decrease in luciferase
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activity (Figure 2.13 and 3.8). Similar results were obtained when the D960A/E961AEGF receptor luciferase constructs were expressed in cells, indicating that this mutant
behaves similarly to the Thr-669 mutant that lacks the MAP kinase phosphorylation site.
Together these data suggest Asp-960 and/or Glu-961 play a significant role in MAP
kinase-mediated EGF receptor desensitization, possibly by blocking formation of the
allosteric asymmetric dimer.
When Thr-669 was mutated to Arg, enhanced autophosphorylation was observed
compared to the wild-type EGF receptor. This is consistent with a favorable interaction
between the Arg-669 and Asp-960/Glu-961. However, mutation of Thr-669 to Asp and
Glu to mimic constitutive phosphorylation did not have the expected result. Instead of
observing the expected decrease in autophosphorylation due to charge repulsion between
the negatively charged Asp- or Glu-669 and Asp-960/Glu-961, an increase in
autophosphorylation compared to the wild type EGF receptor was observed. This is
consistent with data reported by Morrison et al. in which Thr-669 was mutated to Glu and
an increase in autophosphorylation compared to the wild type EGF receptor was observed
(132). However, these data are not consistent with a recent report by Red Brewer et al.,
in which the intracellular domain of the T669D-EGF receptor showed decreased
autophosphorylation compared to the wild type EGF receptor, whereas the T669A-EGF
receptor exhibited enhanced autophosphorylation (39). These observed differences may
be due to a lack of signaling in the intracellular domain constructs utilized by Red Brewer
et al., rendering MAP kinase inactive and therefore blocking one of the EGF receptor
desensitization mechanisms. Alternatively, there may be additional structural constraints
imposed by the EGF receptor extracellular and transmembrane domains that allow the
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receptor to overcome the negative charge imposed by the T669D- and T669E-EGF
receptor mutations.
While the increased autophosphorylation observed in the T669D- and T669EEGF receptor mutants was unexpected, it does not necessarily contradict the hypothesis
that Thr-669 phosphorylation by MAP kinase desensitizes the EGF receptor by blocking
formation of the asymmetric dimer interface. Attempts in other systems to mimic serine
or threonine phosphorylation using either Aspartic or Glutamic acid have also generated
mixed results (133, 134). For example, phosphorylation of rhodopsin’s C-terminal tail is
required for binding of and induction of a conformational change in arrestin. Studies
using Surface Plasmon Resonance with either a phosphorylated rhodopsin C-terminal tail
peptide or one in which all the serine/threonine residues were substituted with Glutamic
acid yielded opposing results in the ability to bind arrestin. These and other studies
indicate that the ability of Glutamic and Aspartic acid to mimic constitutive
phopshorylation is system-dependent.
In this system, replacement of Thr-669 with Asp or Glu does not appear to be
enough to mimic the effects of phosphorylation.

The effects of serine/threonine

phosphorylation may be particularly difficult to mimic because surface-exposed Glutamic
acid side chains can occupy several positions due to the flexibility of this sidechain (134).
The increased phosphorylation observed in the T669D- and T669E-EGF receptor mutants
is therefore expected if the charge on these amino acids is not enough to lead to charge
repulsion with Asp-960/Glu-961.

These mutants lack the “cue” to desensitize the

receptor, resulting in enhanced autophosphorylaiton.
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The mutations described in this chapter identified Asp-950 as a residue important
for stabilization of the asymmetric dimer interface. When the D950A-EGF receptor was
expressed in cells, severely impaired autophosphorylation was observed compared to the
wild type EGF receptor. Similar results were obtained by Jura et al. when Asp-950 was
mutated to Ala (38). These data are consistent with the D950A-EGF receptor being
unable to function as a donor kinase in the asymmetric dimer. This hypothesis is further
supported here by demonstrating that D950A- and L680N-EGF receptors expressed
independently had little kinase activity, but activity was restored when the receptors were
co-expressed in the same cells.
A rapid increase in luciferase activity was observed both in the kinase-dead EGF
receptor and the EGF receptor lacking the intracellular domain (Chapter 2, Figures 2.1
and 2.10). Similar results were observed when luciferase complementation imaging of
the D950A-EGF receptor was examined, consistent with the lack of kinase activity in this
mutant.

Luciferase complementation imaging further supports that the D950A-EGF

receptor plays an important role in proper formation of the asymmetric dimer interface.
Surprisingly, in stark contrast to the D950A-EGF receptor, autophosphorylation
of the D950A/D960A/E961A-EGF receptor recovered to near wild type levels. This
recovery was independent of the MAP kinase-mediated desensitization mechanism since
expression of the T669A/D960A-EGF receptor retained little kinase activity. The Asp950 residue is stabilizing in the context of the asymmetric dimer interface and mutation
of this residue is destabilizing. When mutated in conjunction with Asp-960 and Glu-961,
the “imperfect” asymmetric dimer interface formed by the Asp-950 mutant may recover
kinase activity because the C-terminal tail may be displaced more easily when the
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potential “pivot” formed by the Asp-960 is loosened through mutation to Ala. This
scenario would allow asymmetric dimer formation and autophosphorylation to near wild
type levels, despite a non-ideal asymmetric dimer interface.
The potential role of Asp-960 as a pivot point during movement of the C-terminal
tail may explain why mutation of Ser-787 has been reported in lung cancer patients. Na
et al. reported mutation of Ser-787 to Phe (135), which would remove the hydrogen bond
between this residue and Asp-960, possibly causing easier displacement of the EGF
receptor C-terminal tail and enhanced EGF receptor kinase activation and signaling.
However, these results are purely speculative in the absence of: 1) confirmation that
S787F-EGF receptor displays enhanced phosphorylation and 2) this mutation has been
identified in additional patients and/or is linked more clearly to cancer progression.
In a sequence alignment of the EGF receptor family members, Thr-669 and the
MAP kinase consensus sequence for phosphorylation (P X T/S P) is conserved among all
members, except ErbB3 (Figure 3.10). While the significance of this is unknown, it is
noteworthy that ErbB3 is the only intrinsically kinase-dead member of the EGF receptor
(48, 57, 66). This may reflect the redundant nature of the MAP kinase desensitization
mechanism because the kinase-dead nature of ErbB3 limits the pool of kinase domains
that can serve as an activated acceptor. Additionally, ErbB3 signals better via the PI3kinase pathway due to multiple docking sites in its C-terminal tail (48), possibly reducing
the impact of the MAP kinase pathway, as well as need for a desensitization mechanism
via this pathway.

In addition to conservation of the Thr-669 site, the presence of

negatively charged amino acids in the region of the EGF receptor Asp-960 and Glu-961
is also conserved among all family members and among various species (Figure 3.10).
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Based on the data described in this chapter, a model for the MAP kinase-mediated
desensitization of the EGF receptor was established. Figure 3.11 depicts a cartoon
representation of this model. Ligand binding to the EGF receptor extracellular domain
induces a large conformational change, enabling dimerization and subsequent asymmetric
kinase domain dimerization. The juxtamembrane domain of the acceptor kinase domain
in the dimer may displace the C-terminal tail of the donor kinase domain to form the
optimal asymmetric dimer interface/juxtamembrane domain cradle (Figure 3.11A to B).
The activating asymmetric dimer leads to acceptor activation and phosphorylation of the
C-terminal tail of the donor kinase. This enhances signal complex formation and leads to
activation of the MAP kinase pathway, followed by feedback signaling through MAP
kinase phopshorylation on the EGF receptor Thr-669 (Figure 3.11 C to D). Following
phosphorylation of the initial donor kinase C-terminal tail, the kinase domains may
switch roles so that the donor becomes the acceptor and vice versa (Figure 3.11D). As
the kinase domains switch roles, the original donor kinase with a phosphorylated Thr-669
will try to displace the C-terminal tail of the original acceptor kinase (now adopting the
donor position). Because of the highly negatively charged phosphate group on Thr-669,
a charge repulsion with Asp-960 and/or Glu-961 exists, making it difficult for the original
donor to adopt the acceptor position/form a proper asymmetric dimer interface. This
leads to a dissociation of this attempted asymmetric dimer without phosphorylation of the
original acceptor’s C-terminal tail (Figure 3.11E). MAP kinase desensitizes the EGF
receptor kinase activity by making the monomer with a phosphorylated Thr-669 a poor
acceptor kinase. This mechanism would lead to decreased autophosphorylation because
of the limited pool of kinases that can function as acceptors. Several questions remain to
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be answered based on this model. For example, it is not known which Thr-669 residue is
phosphorlated. Figure 3.11 depicts the phospho-Thr-669 as the original donor kinase
simply because it seems likely that the Thr-669 phosphorylation site on the acceptor
kinase will be less accessible to MAP kinase. It also appears that additional residues may
important for the MAP kinase-mediated desensitization mechanism and identification of
these residues will be important.
Thr-669 in the recent crystal structure determined by Red Brewer et al. points
away from the C-lobe of the donor kinase (Figure 3.2) (39).

This may seem

contradictory to an interaction with Asp-960 and/or Glu-961 during MAP kinasemediated desensitization. However, phosphorylated Thr-669 may negatively interact
with Asp-960 and/or Glu-961 in a transitory state that exists as the acceptor kinase is
forming the cradle around the C-lobe of the donor kinase. The structure observed by Red
Brewer et al. would then form when Thr-669 is not phosphorylated.
The data presented in this Chapter describe, for the first time, the mechanism that
MAP kinase utilizes to desensitize the EGF receptor through phosphorylation on Thr669. This mechanism of blocking asymmetric dimer formation is not unique, since Mig6,
a protein transcriptionally activated by the EGF receptor, has also been reported to block
EGF receptor activation by blocking asymmetric dimer formation (89).

It will be

interesting to see if additional modulators of EGF receptor activity function through a
similar mechanism of blocking asymmetric dimer formation.
Experimental Procedures
Reagents—Murine EGF was purchased from Biomedical Technologies, Inc. and
was dissolved in sterile water. U0126 (EMD Chemicals) was dissolved in DMSO.
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Doxycycline was from Clontech and was dissolved in sterile water.

D-Luciferin

(Biosynth) was dissolved in PBS and coelenterizine (Sigma) was dissolved in ethanol.
The MAP kinase and phospho-specific Thr-669 antibodies were from Upstate. The
phospho-specific MAP kinase antibody was from Promega and the phosphotyrosine
(PY20) antibody was from BD Biosciences. A mixture of EGF receptor antibodies from
Cell signaling and Santa Cruz were used to detect the EGF receptor.
DNA Constructs—The wild type EGF receptor construct (127) was subcloned
from pcDNA3.1(-) (Invitrogen) into pcDNA5/FRT (Invitrogen) using the NheI and
HindIII restriction enzyme sites. Using the wild type EGF receptor (pcDNA3.1(-)) as the
template, QuikChange site-directed mutagenesis (Stratagene) was used to generate the
D950A and D960A/E961A mutants. Mutants were digested with the BstEII and HindIII
restriction enzyme sites and were ligated into the wild type EGF receptor construct
(pcDNA5/FRT) cut with the same enzymes.

All mutants were sequenced in their

entirety.
The D950A/D960A/E961A mutant was generated using QuikChange site-directed
mutagenesis with the D960A/E961A-EGF receptor mutant (pcDNA3.1(-)) as the
template.

The D950A/D960A/E961A-EGF receptor pcDNA5/FRT construct was

subcloned into the wild type pcDNA5/FRT construct using the BstEII and HindIII
restriction sites and was sequenced.
The T669A-CLuc construct was made using QuikChange site-directed
mutagenesis of the EGFR-CLuc (pcDNA6/V5-HisB) construct (Chapter 2). The product
was re-ligated into the same vector using the NheI and BsiWI restriction enzyme sites.
The T669A-EGF receptor (pcDNA5/FRT) construct was subsequently generated by

73

digesting the T669A-CLuc (pcDNA6/V5-HisB) and wild type EGF receptors
(pcDNA5/FRT) with NheI and BstEII.

The product was sequenced to verify the

mutation.
QuikChange site-directed mutagenesis was used to make the T669A/D950A-EGF
receptor mutation, with the T669A-EGF receptor (pcDNA5/FRT) construct as the
template. Following mutagenesis, the construct was re-ligated into the T669A-EGF
receptor construct using the NheI and NotI restriction enzyme sites.

Sequencing

confirmed the mutation.
The L680N-EGF receptor mutant was made using QuikChange site-directed
mutagenesis in the wild type EGF receptor pcDNA5/FRT construct as described
previously (136). The mutant was sequenced and then digested with NheI and EcoRV
and ligated into MCSI of the pBI-Tet vector (Clontech).
QuikChange site-directed mutagenesis was used to make the T669E-, T669R-,
and T669D-EGF receptor constructs with the wild type EGF receptor (pcDNA5/FRT) as
the template. Mutants were digested with NheI and BstEII and were ligated into the wild
type EGF receptor pcDNA5/FRT plasmid cut with the same enzymes. Mutations were
verified by sequencing.
The D950A-CLuc and D960A/E961A-CLuc mutants were made by QuikChange
site directed mutagenesis of the EGFR-CLuc pcDNA6/V5-HisB construct. Mutants were
digested with BstEII and BsiWI and were re-ligated into the EGFR-CLuc pcDNA6/V5HisB construct. The D950A-NLuc and D960A/E961A-NLuc constructs were first made
by digesting the D950A-CLuc and D960A/E961A-CLuc constructs with NheI and
BsiWI, followed by ligation into the EGFR-NLuc pBI-Tet construct.
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These NLuc

mutants were later subcloned into the pcDNA5/FRT vector using the BstEII and EcoRV
restriction enzyme sites in the mutants and the BstEII and KpnI sites in the wild type
EGF receptor pcDNA5/FRT construct.
T669A-NLuc in pcDNA5FRT was generated by restriction enzyme digest of the
EGFR-NLuc pcDNA3.1TOPO plasmid with BstEII and KpnI, followed by ligation into
T669A-EGF receptor pcDNA5/FRT.
The K721A-EGFR-CLuc construct was made using QuikChange site-directed
mutagenesis (Stratagene) in the EGFR-CLuc pcDNA6/V5-His B construct. The K721AEGFR-NLuc construct was made by digesting EGFR-NLuc (pcDNA3.1 TOPO) with
BstEII and KpnI. The insert was ligated into the K721A pcDNA5.FRT (Invitrogen)
construct digested with the same enzymes.
Cell Lines—FI CHO cells (Invitrogen) were co-transfected with pOG44
(Invitrogen) and the wild type or mutant EGF receptors (pcDNA5/FRT) using
Lipofectamine 2000 (Invitrogen). Stable clones were isolated by selection in 600 µg/ml
hygromycin (InvivoGen). Cells were maintained in F-12 containing 10% FetalPlex, 1000
µg/ml penicllin/streptomycin, and 100 µg/ml hygromycin. CHO-K1 Tet-On cells were
grown in DMEM containing 10% FetalPlex, 1000 µg/ml penicllin/streptomycin, and 200
µg/ml G418.

The EGFR-NLuc/EGFR-CLuc, T669A-NLuc/T669A-CLuc, D950A-

NLuc/D950A-CLuc,

D960A/E961A-NLuc/D960A/E961A-CLuc,

and

K721A-

NLuc/K721A-CLuc constructs were transiently transfected into CHO-K1 Tet-On cells 24
hrs prior to luciferase fragment complementation imaging using Lipofectamine 2000.
Transfection efficiency was determined by co-transfection of renilla luciferase (pRLucN1, Packard Bioscience).
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Kinase activation and Western Blotting—FI CHO EGF receptor wild type or
mutant cells were grown to confluence in 35 mm dishes. Cells were serum-starved in F12 containing 1 mg/ml BSA for 2 hr. Cells were washed twice in ice-cold PBS and were
then scraped into RIPA buffer (150 mM NaCl, 10 mM Tris pH 7.2, 0.1% sodium
dodecylsulfate, 1% Triton X-100, 17 mM deoxycholate, and 2.7 mM EDTA) containing
20 mM p-nitrophenyl phosphate, 1 mM sodium orthovanadate, and protease inhibitors.
Equal amounts of protein (BCA assay, Pierce) were loaded onto a 9% SDSpolyacrylamide gel and then transferred to PVDF (Millipore).

Western blots were

blocked for 1 hour in TBST/10% nonfat milk. The blots were incubated in primary
antibody for 1 hr (overnight at 4°C for EGF receptor and phospho-Thr-669 antibodies),
washed in TBST/0.1% BSA, incubated in secondary antibody for 45 min and washed
three times in TBST/0.1% BSA. Western blots were detected using the ECL reagent
from GE Healthcare.
125

I-EGF Internalization—Murine EGF was radioiodinated as described

previously (102). Cells were plated 48 hrs prior to assay in six-well dishes. Cells were
washed twice in HBSS (37°C) and were then incubated for the indicated lengths of time
in 1 nM

125

I-EGF at 37°C in F-12 media containing 40 mM Hepes and 0.1% bovine

serum albumin. Nonspecific binding was determined by addition of 100 nM unlabeled
EGF. At each time point, half of the cultures were washed three times in HBSS, the
monolayers were dissolved in 1N NaOH, and the radioactivity was determined by γcounting. This yields the total cell-associated

125

I-EGF. The other half of the cultures

were washed twice (2 min each) in acid wash buffer (50 mM glycine, 100 mM NaCl,
pH3) to remove any cell-surface 125I-EGF (137). Monolayers were then dissolved in 1N
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NaOH and were counted in a γ-counter. This yields the internalized

125

I-EGF and

subtraction from the total 125I-EGF yields the amount of surface 125I-EGF.
Luciferase complementation imaging—Cells were plated 48 hr prior to use at 5
x103 cells per well in DMEM in a black-wall 96-well plate. On the day of the assay, cells
were serum-starved for 2 hr and then incubated for 20 min in 175 µl DMEM without
phenol red, containing 1 mg/ml BSA, 25 mM Hepes, and 0.6 mg/ml D-luciferin at 37°C.
To establish a baseline, cell radiance (photons/second/cm2/sr) was measured using a
cooled CCD camera and imaging system at 37°C (IVIS 50; Caliper) (30 sec exposure;
binning, 8; no filter; f-stop, 1; field of view, 12 cm). EGF was added in a volume of 25
µl in the same media (DMEM, 1mg/ml BSA, 25mM Hepes, 0.6mg/ml D-Luciferin).
Radiance was measured sequentially as described above. Transfection efficiency was
assessed by monitoring renilla luciferase expression. Media was replaced on cells with
DMEM (no phenol red) containing 1 mg/ml BSA, 25 mM Hepes, and 400 nM
coelenterazine. Radiance was immediately measured as described above except the filter
was set to <510.
Data Analysis—Data was collected in quadruplicate for each condition. A flatfield correction was done to correct for differences in the baseline photon flux. Light
production expressed as photon flux (photons/sec) was determined from regions-ofinterest defined over wells using LIVINGIMAGE (Xenogen) and IGOR (Wavemetrics)
software. Changes in photon flux were calculated by subtracting values from untreated
cells from those of EGF-treated cells. Standard errors were determined using the formula
for the unpooled standard error.
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Figure 3.1. Effect of Thr-669 mutation on EGF receptor autophosphorylation and
internalization. FI CHO cells expressing the wild type or T669A-EGF receptor were
plated 48 hr prior to assay in six-well dishes. Cells were serum-starved prior to assay.
A) Cells were stimulated with the indicated concentrations of EGF for 5 min at 37°C.
Cells were lysed, run on an SDS-PAGE gel, and Western blot analysis was done with the
indicated antibodies. B) Cultures were incubated for the indicated lengths of time in 1
nM 125I-EGF. Total 125I-EGF was determined by washing cultures three times in HBSS,
while internalized 125I-EGF was determined by washing cultures twice in acid wash.
Monolayers were dissolved in 1N NaOH followed by γ-counting. Surface 125I-EGF was
determined by substraction of total and internalized 125I-EGF. Internalized/surface 125IEGF was plotted as a function of time to determine the internalization rate for the wild
type (closed circles, 0.052 ± 0.003 min-1) and T669A-EGF receptors (open circles, 0.078
± 0.004 min -1).
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Figure 3.2. Crystal structure of the EGF receptor juxtamembrane and kinase
domain asymmetric dimer interface, highlighting the residues surrounding Thr-669.
The acceptor EGF receptor kinase monomer is shown in blue and the donor kinase is
shown in yellow. The juxtamembrane region of the acceptor/blue kinase monomer is
shown forming a cradle around the C-lobe of the donor/yellow kinase monomer in the
asymmetric dimer. Shown magnified is the position of the Thr-669 residue in the
juxtamembrane domain of the acceptor/blue monomer. Highlighted in the C-lobe of the
donor/yellow monomer are acidic residues (Asp-950, Asp-960, Glu-961) that lie in close
proximity to Thr-669. The PDB coordinates for this structure are 3GOP (39).
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Figure 3.3. EGF receptor autophosphorylation in wild type, T669A, and
D960A/E961A mutants. FI CHO cells stably expressing the wild type, T669A, or
D960A/E961A-EGF receptor were plated 48 hrs prior to assay in six-well dishes. Cells
were serum-starved 2 hrs prior to assay. A) The indicated concentrations of EGF were
added to cells for 5 min at 37°C. Cells were lysed, loaded for equal EGF receptor
expression, and were run on a 9% SDS-PAGE gel. Western blot analysis was performed
with the indicated antibodies. B) Cells were incubated for 20 min at 37°C without or
with 10 µM U0126, followed by stimulation with 1 nM EGF for 5 min. Cells were
immediately lysed, equal EGF receptor levels were run on an SDS-PAGE gel and
Western blotting was done with the indicated antibodies.
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Figure 3.4. Effect of blocking MAP kinase activation on wild type or T669A-EGF
receptor autophosphorylation. FI CHO cells stably expressing the wild type or T669AEGF receptor were plated 48 hrs before assaying in six-well plates. On the day of the
assay, cells were serum-starved for 2 hrs. Cells were pre-incubated in the absence or
presence of 10 µM U0126 for 20 min at 37°C, followed by stimulation for 5 min with 1
or 10 nM EGF. Lysates were immediately made of the cells and equal proteins were
loaded on an SDS-PAGE gel. Western blots were analyzed with the indicated antibodies.
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Figure 3.5. Dose-response to EGF in cells expressing wild type, T669A, T669R,
T669D, and T669E-EGF receptor mutants. Cells stably expressing the wild type or
EGF receptor mutants were plated 48 hrs prior to assay in six-well dishes. Cells were
serum-starved 2 hr prior to assay. The indicated concentrations of EGF were added to
cells for 5 min at 37°C. Cells were immediately lysed, equal proteins were loaded on a
9% SDS-PAGE gel and Western blot analysis was performed with the indicated
antibodies. A) Wild type, T669A, and T669R-EGF receptors. B) Wild type, T669D, and
T669E-EGF receptors.
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Figure 3.6. EGF receptor autophosphorylation in cells expressing wild type, D950A,
D950A/D960A/E961A, L680N, or D950A/L680N mutations. A) FI CHO cells that
stably express the wild type, D950A, or D950A/D960A/E961A-EGF receptor were
plated 48 hrs before assaying in six-well dishes. Cells were serum-starved 2 hrs before
assay. Cells were treated with the indicated concentrations of EGF for 5 min at 37°C and
were immediately lysed. Lysates were loaded for equal EGF receptor expression and
were run on an SDS-PAGE gel. Western blot analysis was done with the indicated
antibodies. B) CHO-K1 Tet-On cells stably expressing the L680N-EGF receptor were
plated 48 hrs prior to assay in the absence (D950A) or presence (L680N and
D950A/L680N) of 500 ng/ml doxycycline to induce L680N-EGF receptor expression
(pBI-Tet vector). 24 hrs prior to assay cells were transiently transfected with cDNA for
the D950A-EGF receptor. Cells were serum-starved for 2 hrs and were then stimulated
with 25 nM EGF for 5 min at 37°C. Cells were immediately lysed and equal proteins
loaded on an SDS-PAGE gel. Western blotting was performed with the indicated
antibodies.
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Figure 3.7. EGF dose response in cells expressing wild type or T669A/D950A EGF
receptors. FI CHO cells stably expressing the wild type or T669A/D950A-EGF receptor
were plated in six-well dishes 48 hrs prior to assay. Cells were serum-starved 2 hr prior
to assay, followed by stimulation for 5 min at 37°C with the indicated concentrations of
EGF. Cells were lysed and equal proteins were loaded on an SDS-PAGE gel. Western
blot analysis was done with the indicated antibodies.
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Figure 3.8. Reconstitution of luciferase activity in cells expressing wild type, T669A,
or D960A/E961A luciferase constructs. CHO-K1 Tet-On cells were plated in 96-well
plates 48 hrs prior to luciferase complementation imaging. 24 hrs prior to imaging, cells
were transiently transfected with the cDNA encoding the wild type, T669A, or
D960A/E961A-EGF receptor NLuc and CLuc luciferase constructs. On the day of
imaging, cells were serum-starved for 2 hrs followed by pre-incubation in 0.6 mg/ml Dluciferin for 20 min. A, C, E) Photon flux (photons/sec; p/s) in the absence of EGF. B,
D, F) Change in photon flux following addition of 10 nM EGF. Data represent the
average of four independent replicates and standard error is shown.
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Figure 3.9. Reconstitution of luciferase activity in cells expressing D950A and
K721A EGF receptor luciferase constructs. CHO-K1 Tet-On cells were plated in a 96well plate 48 hrs prior to imaging. Cells were transiently transfected with the cDNA
encoding the K721A-EGF receptor or D950A-EGF receptor NLuc and CLuc constructs
24 hrs prior to imaging. On the day of imaging, cells were serum-starved for 2 hrs,
followed by a 20 min incubation with 0.6 mg/ml D-luciferin. A and C) Photon flux
(photons/sec; p/s) in the absence of ligand. B and D) Change in photon flux following
addition of 1 (open circles) or 10 nM EGF (closed circles).
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Figure 3.10. Sequence alignment of the region surrounding EGF receptor Thr-669
and the acidic amino acids Asp-950, Asp-960, and Glu-961. The top panels show the
sequence alignment of the human EGF receptor family members (EGFR, ErbB2, ErbB3,
ErbB4), while the bottom panel shows the sequence alignment of the EGF receptor in
various species. The left panels show the residues surrounding Thr-669, while the right
panels show the residues surrounding Asp-950 and Asp-960/Glu-961 on the EGF
receptor.
Highlighted in pink are residues that are conserved among family
members/species. Turquoise shows residues that are not conserved compared to the other
family members/species, while blue shows residues that are not conserved, but carry the
same charge compared to other family members/species.
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Figure 3.11. Model for the mechanism of MAP kinase-mediated EGF receptor
desensitization. A) Conformation of the EGF receptor in the absence of ligand with the
extracellular domain held in the tethered conformation. B) Ligand binding induces a
dramatic extracellular domain conformational change, facilitating EGF receptor
dimerization, and bringing into proximity the kinase domains to form the activating
asymmetric dimer (yellow = donor kinase, blue = acceptor kinase). Formation of the
juxtamembrane domain cradle by the blue/acceptor kinase may displace the C-terminal
tail of the yellow/donor kinase so that it can be phosphorylated. C) Phosphorylation of
the C-terminal tail of the yellow/donor kinase provides a scaffold for activation of
downstream signaling pathways, particularly the MAP kinase pathway. MAP kinase is
engaged in a feedback loop with the EGF receptor through phosphorylation on Thr-669.
D) Following phosphorylation of the donor/yellow kinase C-terminal tail, the kinase
domains may attempt to switch roles so the donor becomes the acceptor and vice versa.
When the yellow kinase tries to engage the acceptor kinase role, the phosphorylated Thr669 interacts unfavorably with negatively charged residues (Asp-960 and/or Glu-961),
resulting in a charge repulsion. E) Because of the charge repulsion, the yellow kinase
could not adopt the acceptor role and therefore could not become activated via the
allosteric asymmetric dimer mechanism.
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CHAPTER 4. Examining the Differential Effects of the EGF Family of Growth
Factors using the Luciferase Fragment Complementation Imaging Assay
Introduction
Signaling from the EGF receptor family members is first initiated by binding of
the EGF-like family of growth factor ligands. There are 11 known ligands that bind to
the EGF receptor family. These ligands are synthesized as transmembrane precursors
that can mediate either juxtacrine effects and/or both autocrine and paracrine effects upon
ectodomain shedding (47, 138, 139). The soluble growth factors subsequently bind to
and initiate the formation of both homo- and hetero-dimeric receptor complexes as
depicted in Figure 4.1 (47, 140).
The number of possible ligand and receptor combinations suggests a layer of
complexity in the initialization of the signaling network (48, 66, 140). It was originally
thought that different ligands induce different combinations of ErbB receptor
dimerization. However, the discoveries that EGF receptor or ErbB4 homodimers can
initiate different cellular responses upon binding to different ligands (141, 142) suggested
that signal diversification is not achieved simply by ligand-induced dimer combination,
but rather additionally regulated by subtle differences in the transmission of signals from
ligands to receptor activation.
In addition to EGF, the ligand amphiregulin (AR) is specific for the EGF receptor
and can induce tyrosine phosphorylation of the receptor (143, 144).

AR was first

discovered in 1988 in the media of MCF7 breast cancer cells treated with 12-Otetradecanoylphorbol 13-acetate (143). Shoyab et al. termed the new growth factor
“amphi”-regulin because of its ability to be stimulating in some cells, while inhibitory in
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others.

However, these inhibitory properties of AR have not yet been validated.

Amphiregulin exhibits significantly lower affinity for the EGF receptor compared to
EGF— AR can only compete 50-75% of the 125I-EGF (143). Studies have indicated that
the decreased affinity of AR may be due to the absence of a critical Leu reside in the Cterminal region of the growth factor that is important for high affinity binding in both
EGF and TGF-α (145).
Both EGF and AR are specific for the EGF receptor, while the growth factor
betacellulin (BTC) and neuregulin2β are considered as pan-ErbB ligands because they
can induce all combinations of receptors through binding to either the EGF receptor or
ErbB4 (146). Unlike AR, BTC has comparable ability to compete for 125I-EGF binding
as EGF itself (IC50 ~ 1.4 nM for BTC versus ~ 1.9 nM for EGF) (50). The observations
that these distinct ligands are able to induce different tyrosine phosphorylation patterns
on either the EGF receptor or ErbB4 (141, 142) suggests a plausible mechanism for the
initiation of distinct signaling pathways which ultimately lead to distinct cellular
outcomes.
Clearly the ligands for the EGF receptor, while structurally similar, are able to
mediate a distinct and complex set of signaling outputs. However, there have been few
studies capturing the differences in their abilities to induce homo- and heterodimerization due to lack of an appropriate assay. This Chapter examines the dimerization
potential of these EGF-like ligands and the consequential impact on the intracellular
domain conformational changes in the full length EGF receptor.

By utilizing the

luciferase imaging assay, we focus on comparing the hierarchy of these ligands by
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measuring both the magnitudes and rates of extracellular-mediated dimer formation and
the intracellular domain conformational changes.
Results
Identification of the saturation point in luciferase activity following stimulation with
EGF, BTC, or AR in ΔC-EGF receptor cells
In order to compare the dimerization potential of ligands, we first determined the
concentration at which each ligand is saturating to dimerization by measuring the
luciferase activity dose-response to EGF, BTC, or AR in cells stably expressing the
intracellular-domain-lacking EGF receptor (ΔC-EGFR-NLuc/CLuc cell line). As with
data presented in Chapter 2 (Figure 2.1), a baseline level of luciferase activity was
observed in these cells in the absence of ligands (Figure 4.2A, C, E) consistent with the
notion of pre-formed dimers (42, 114, 115).
When increasing concentrations of EGF were added to ΔC-EGFR-NLuc/CLuc
cells, a rapid increase in luciferase activity was observed (Figure 4.2B). Luciferase
activity reached a plateau 10-15 min after addition of 10 or 25 nM EGF, while no plateau
was observed during the observation period after addition of lower concentrations of EGF
(<2 nM). Qualitatively 10 nM EGF appears to be sufficient to induce maximal luciferase
activity (Figure 4.2B). This is confirmed by comparing the Ymax values for a one-phase
exponential association curve fit to these data with GraphPad Prism (p-value > 0.05,
Table 4.1).
Similarly, when ΔC-EGFR-NLuc/CLuc cells were stimulated with increasing
concentrations of BTC, a rapid increase in luciferase activity was observed (Figure 4.2D).
In this experiment, luciferase activity appeared to reach a plateau 15-20 min after
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addition of 25 nM BTC, with no plateau observed during this time in cells treated with
less than 2 nM BTC. Again, the one-phase exponential association curve fit to the 10 and
25 nM BTC data indicated that the Ymax values were not significantly different for these
two concentrations of ligand (p-value > 0.05, Table 4.1), suggesting that these
concentrations of ligand represent a saturation point in luciferase activity.
ΔC-EGFR-NLuc/CLuc cells treated with increasing concentrations of AR also
exhibited a rapid increase in luciferase activity (Figure 4.2E). Because of the decreased
affinity of the EGF receptor for AR, higher concentrations of ligand were used to observe
the changes in luciferase activity (143). Addition of high concentrations of AR (100 and
250 nM) led to a rapid plateau in luciferase activity (5-10 min). However, in stark
contrast to the results obtained with EGF and BTC, addition of increasing concentrations
of AR resulted in an initial increase in luciferase activity, followed by a decrease. This
unexpected result made it impossible to determine the saturating concentration of AR
since it is unclear where, if any, saturation point exists.
From these dose-response data on ΔC-EGFR-NLuc/CLuc cells treated with EGF,
BTC, or AR, a dose-response curve was generated by plotting the concentration of ligand
versus the change in photon flux after 20 min of imaging (Figure 4.3). An estimate of the
EC50 values for EGF and BTC was obtained by fitting the data to a sigmoidal doseresponse curve using GraphPad Prism, yielding an EC50 of 1.8 nM and 0.8 nM for EGF
and BTC, respectively (Figure 4.3A and B). The unique dose-response of ΔC-EGFRNLuc/CLuc cells to AR exhibited a bell-shaped dose-response curve (Figure 4.3C). It is
difficult to obtain EC50 values from a bell-shaped dose-response curve without a large
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number of data points, so no values were obtained for AR. However, qualitatively the
peak in luciferase activity occurs near 25 nM AR.
Ability of EGF, BTC, and AR to saturate ΔC-EGF receptor/ΔC-ErbB2 heterodimerization
The effect of EGF, BTC, and AR was also examined in cells expressing the EGF
receptor and ErbB2, both lacking the intracellular domains. Similar to the EGFR, ErbB2
consists of an extracellular domain with four subdomains, a single-pass α-helical region,
and an intracellular domain (147). Unlike the EGFR, ErbB2 has no known high-affinity
ligand and thus cannot undergo a ligand-induced conformational change. Instead, ErbB2
is thought to constitutively adopts an open/extended receptor conformation that is capable
of undergoing dimerization (148-150). Heterodimers of EGFR and ErbB2 have been
reported to exhibit more potent signaling than EGFR/EGFR homodimers and as a result
are implicated in cancer progression (57, 66, 140, 151). It is therefore interesting to
examine the hetero-dimerization induced by different EGF-like ligands, particularly
because EGF receptor homodimers are capable of binding two ligands, while EGF
receptor-ErbB2 hetero-dimers will have only one ligand bound in the dimer.
Because the luciferase fragment complementation imaging system utilizes two
fragments of luciferase, we first wanted to determine if luciferase activity depended on
which fragments were fused to the EGF receptor or ErbB2. The NLuc fragment was
fused to either the EGF receptor or ErbB2 to produce ΔC-EGFR-NLuc or ΔC-ErbB2NLuc.

Similar constructs were made using the CLuc fragment.

The following

combinations of NLuc and CLuc fusion proteins were transiently transfected into CHO
cells: ΔC-EGFR-NLuc/ΔC-EGFR-CLuc, ΔC-ErbB2-NLuc/ΔC-EGFR-CLuc, ΔC-EGFR-
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NLuc/ΔC-ErbB2-CLuc, and ΔC-ErbB2-NLuc/ΔC-ErbB2-CLuc. The luciferase activity
in the absence and presence of EGF was determined for each of these combinations and
is shown in Figure 4.4.
For comparison, CHO cells were transiently transfected with the cDNA for ΔCEGFR-NLuc and ΔC-EGFR-CLuc. Figure 4.4A shows the baseline photon flux in these
cells.

Similar to the results obtained in the cell line stably expressing ΔC-EGFR-

NLuc/CLuc (Figure 4.2), this basal photon flux was not zero. Addition of EGF led to a
rapid increase in luciferase activity that plateaued 10-15 min after stimulation (Figure
4.4B), comparable to earlier results (Figure 4.2 and Chapter 2, Figure 2.1).
When cells were transiently transfected with the ΔC-ErbB2-NLuc/ΔC-EGFRCLuc constructs, a basal luciferase activity was again observed (Figure 4.4C). This basal
activity was somewhat higher than that observed in cells expressing just the ΔC-EGF
receptor luciferase constructs, which may simply represent a difference in expression
level of these constructs. EGF treatment led to a rapid increase in luciferase activity,
with a plateau 10-15 min after addition of ligand (Figure 4.4D). While the maximum
change in luciferase activity appears greater in the ΔC-ErbB2-NLuc/ΔC-EGFR-CLuc
cells compared to the ΔC-EGFR-NLuc/CLuc cells, the difference may again be due to
variation in receptor expression levels.
Cells expressing the ΔC-EGFR-NLuc/ΔC-ErbB2-CLuc constructs also displayed
a baseline luciferase activity (Figure 4.4E). This baseline level was lower than that
observed in the ΔC-ErbB2-NLuc/ΔC-EGFR-CLuc constructs (Figure 4.4C), which may
indicate a difference in expression level of the NLuc and CLuc constructs. Because the
difference in baseline photon flux could affect interpretation of the ligand-induced
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changes in photon flux, the baseline ΔC-EGFR-NLuc/ΔC-ErbB2-CLuc photon flux was
corrected to match that of cells expressing the ΔC-ErbB2-NLuc/ΔC-EGFR-CLuc
constructs. Stimulation with EGF again led to a rapid increase in luciferase activity
(Figure 4.4F). Luciferase activity plateaued 10-15 min after addition of ligand. When
the data was fit to a one-phase exponential association curve and compared to the ΔCErbB2-NLuc/ΔC-EGFR-CLuc cells analyzed the same way, a small but statistically
significant change in the Ymax was observed (9.62 ± 0.07 x105 p/s vs 1.12 ± 0.01 x106 p/s,
respectively).

This may reflect a difference in the ability of the NLuc and CLuc

fragments to complement when fused to the EGF receptor versus ErbB2. However,
additional experiments using equal expression levels of all the EGF receptor and ErbB2
fusion proteins are necessary to properly assess the potential differences.
The ΔC-ErbB2-NLuc and ΔC-ErbB2-CLuc fusion proteins were expressed in
cells in the absence of any EGF receptor. These cells also exhibited a baseline photon
flux (Figure 4.4G). This is consistent with other reports that ErbB2 can homodimerize in
the absence of ligand (152, 153). However, in contrast to both the homo- and heterodimerization examined here, the ΔC-ErbB2-NLuc/CLuc cells did not display any ligandinduced increase in luciferase activity when treated with EGF (Figure 4.4H). This result
is entirely consistent with an inability of EGF to bind to ErbB2 and elicit any changes in
dimerization (148-150).
To examine changes in hetero-dimerization mediated by EGF, BTC, or AR, a
stable cell line was established that expressed ΔC-EGFR-NLuc and ΔC-ErbB2-CLuc.
Similar to the experiments done in the cell line expressing ΔC-EGFR-NLuc/CLuc, the
concentration of EGF, BTC, or AR needed to saturate luciferase activity was first
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examined (Figure 4.5).

Luciferase activity was detectable in the absence of ligand

stimulation as previously demonstrated (Figure 4.5A, C, and E). Addition of increasing
concentrations of EGF resulted in a dose-dependent increase in luciferase activity in the
ΔC-EGFR-NLuc/ΔC-ErbB2-CLuc cell line (Figure 4.5B). Luciferase activity increased
with increasing concentration of ligand until ~3-10 nM EGF. This was confirmed by
comparing the Ymax from a one-phase exponential association curve fit at 10 and 25 nM
EGF, yielding no significant difference in these values (Table 4.1, p-value >0.05).
The increase in luciferase activity following stimulation with BTC was also
evaluated in cells expressing ΔC-EGFR-NLuc/ΔC-ErbB2-CLuc. Saturation of luciferase
activity occurred near 10 nM BTC, similar to cells expressing ΔC-EGFR-NLuc/CLuc
(Figure 4.5D). Again, curve-fitting to a one-phase exponential association equation
confirmed no detectable change in Ymax upon addition of increasing concentrations of
BTC (Table 4.1, p-value > 0.05).
When ΔC-EGFR-NLuc/ΔC-ErbB2-CLuc cells were stimulated with AR, a
different dose-dependent increase in luciferase activity was observed compared to the
ΔC-EGFR-NLuc/CLuc cells (Figure 4.5F).

In these cells addition of high ligand

concentrations did not induce the same dramatic decrease in luciferase activity observed
in the ΔC-EGFR-NLuc/CLuc cells.

However, there were small differences in the

maximum change in luciferase activity observed with the concentrations of AR above 1
nM, making assessment of the luciferase activity saturation point difficult.
Dose-response curves were generated for ΔC-EGFR-NLuc/ΔC-ErbB2-CLuc cells
stimulated with EGF and BTC (Figure 4.6). The data were fit to a sigmoidal doseresponse curve to determine the EC50 after 20 min of stimulation with ligand. The EC50

97

for EGF and BTC were very similar (0.7 nM and 1nM, respectively, Table 4.1),
indicating these ligands elicited similar changes in lucifease activity in cells expressing
EGF receptor/ErbB2 heterodimers. Similar to cells expressing only the EGF receptor, no
EC50 was determined for ΔC-EGFR-NLuc/ΔC-ErbB2-CLuc cells stimulated with AR.
While a bell-shaped dose-response curve was not obtained in these cells, there were
decreases in luciferase activity with mid-range concentrations of AR (~50 nM).
Additional concentrations of AR will need to be examined before a well-defined doseresponse curve can be generated.
Ability of EGF, BTC, and AR to induce homo- and hetero-dimerization
Based on the Ymax and EC50 values for the ΔC-EGFR-NLuc/CLuc and ΔC-EGFRNLuc/ΔC-ErbB2-CLuc cells, 10 and 25 nM were the saturating concentrations of ligand
used in experiments to determine the ability of EGF, BTC, and AR to induce dimer
formation. Consistent with other results, both the ΔC-EGFR-NLuc/CLuc and the ΔCEGFR-NLuc/ΔC-ErbB2-CLuc cell lines exhibited a non-zero baseline luciferase activity
(Figure 4.7A and D).

ΔC-EGFR-NLuc/CLuc and ΔC-EGFR-NLuc/ΔC-ErbB2-CLuc

cells were first stimulated with 10 nM EGF or BTC and the change in photon flux was
assessed (Figure 4.7B and E). EGF stimulation yielded a greater change in photon flux
than BTC in both ΔC-EGFR-NLuc/CLuc and ΔC-EGFR-NLuc/ΔC-ErbB2-CLuc cells
(compare Ymax in Table 4.2). The rate of change in luciferase activity was also lower in
EGF-treated cells (Table 4.2). These differences were slightly smaller in the ΔC-EGFRNLuc/ΔC-ErbB2-CLuc cell line.
Luciferase activity in ΔC-EGFR-NLuc/CLuc and the ΔC-EGFR-NLuc/ΔCErbB2-CLuc cells stimulated with 25 nM EGF, BTC, or AR was also examined (Figure
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4.7C and F). Consistent with the 10 nM dose of EGF and BTC, EGF was able to induce
the largest change in luciferase activity in both cell lines (Ymax values, Table 4.2). AR
was the least effective ligand in inducing an increase in luciferase activity in both cell
lines (Table 4.2). The rate of change in luciferase activity was greatest in AR-treated
cells (Table 4.2).
BTC enhances the recovery in luciferase activity in the full-length EGF receptor
In Chapter 2, luciferase fragment complementation imaging of the full-length
EGF receptor revealed a series of ligand-induced conformational changes in the
intracellular domain.

The ability of EGF and BTC to induce these conformational

changes was examined in CHO cells expressing the full-length EGFR-NLuc and EGFRCLuc constructs (Figure 4.8). As expected, no difference in the basal photon flux was
observed in these cells prior to ligand stimulation (Figure 4.8A).

Increasing

concentrations of EGF or BTC were added to cells and the change in photon flux over
time was observed (Figure 4.8B-F). EGF was able to induce a decrease and recovery in
luciferase complementation similar to what was previously observed (Chapter 2, Figure
2.3). At low concentrations of ligand (0.1 and 1 nM) little change in photon flux was
observed (Figure 4.8B and C).

Addition of higher concentrations of EGF or BTC

resulted in both a decrease and recovery in luciferase activity (Figure 4.8D-F). The
decrease in luciferase activity was essentially indistinguishable in cells treated with EGF
or BTC. However, the magnitude of the recovery in luciferase activity was higher in
cells treated with BTC, reflecting differences in the ability of these ligands to induce EGF
receptor intracellular domain conformational changes.
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Discussion
Luciferase fragment complementation imaging enabled characterization of ligandinduced conformational changes in both the extracelullar and intracellular domains of the
EGF receptor in response to different ligands of the EGF-like family. These ligands were
able to induce dimerization to differing extents in the context of both homo- and heterodimerization of the EGF receptor extracellular domains.
Initially, dose-response curves were generated for cells expressing the luciferase
fragments fused to either the EGF receptor alone or both the EGF receptor and ErbB2
truncated just beyond the transmembrane domain (ΔC-EGF receptor and ΔC-ErbB2).
The EC50 for EGF and BTC were similar in both EGF receptor homo-dimerization and
EGF receptor/ErbB2 hetero-dimerization. These values are similar to the IC50 values in
experiments where these ligands competed with
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I-EGF binding (50). This indicates

that these receptors have similar responses to ligand in terms of both binding and
dimerization. Unfortunately, without carefully matched receptor levels, the ability of
EGF and BTC to induce homo- versus hetero-dimerization cannot be directly compared.
Additional studies in which known amounts of receptors are expressed will be required to
quantitatively compare the ability of these ligands to induce homo- and heterodimerization.
AR exhibited a unique bell-shaped dose-response curve in ΔC-EGF receptor cells.
These data suggest that in the same cell, AR can function both as an agonist and
antagonist to EGF receptor dimer formation. AR has previously been reported to be both
stimulatory and inhibitory, but these functions were ascribed to its effect on different cell
lines (143). Our findings that AR can be both stimulatory and inhibitory in the same cell
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line suggest a possible unique self-regulatory role for this ligand. It is interesting to note
that such a phenomenon has not been reported for AR-stimulated phosphorylation of the
EGF receptor, indicating that this dose-response curve is unique to EGF receptor
dimerization.

The bell-shaped dose-response curve that is observed may indicate

differential modes of binding to the EGF receptor, perhaps through additional binding
sites other than the traditional subdomain I and III sites. Alternatively, additional ligand
may bind between subdomains I and III making the binding site more open than normal
and likely affecting subdomain II/dimerization arm interactions.

This would then

manifest as a decrease in dimerization upon addition of higher concentrations of ligand.
It will be interesting to see if other EGF-like ligands exhibit similar bell-shaped doseresponse curves.
The data presented here demonstrate that EGF, BTC, and AR exhibit a hierarchy
in their ability to stimulate dimer formation, as measured by the maximum change in
photon flux. In the context of both homo- and hetero-dimerization the order is EGF >
BTC > AR in stimulating dimer formation. BTC may be slightly more effective in
inducing dimer formation in cells expressing ΔC-EGF receptor and ΔC-ErbB2. In these
cells, the percentage change in luciferase activity compared to EGF was ~30%, while
there was a nearly 50% change in luciferase activity in cells expressing only the EGF
receptor. These results are similar to a study by Wehrman et al. using a β-galactosidase
enzyme complementation assay with a truncated EGF receptor and ErbB2 (152). In these
studies BTC stimulated a lower level of dimer formation compared to EGF. Conversely,
AR may be better at inducing dimer formation in cells expressing only the EGF receptor,
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since the percentage change compared to EGF was ~55% in these cells compared to
~70% in cells expressing the ΔC-EGF receptor and ΔC-ErbB2.
In contrast to the ligand ranking for inducing EGF receptor dimerization, this
hierarchy is switched when comparing the rate of ligand-induced dimerization. AR
induces a faster rate of dimerization compared to BTC and EGF in cells expressing just
the ΔC-EGF receptor or in combination with ΔC-ErbB2. This order for the rate of
ligand-induced dimerization is consistent with the notion that AR induces a smaller
number of homo- or hetero-dimers.
These data using the ΔC-EGF receptor and ΔC-ErbB2 indicate that there is a clear
difference in the ability of a particular ligand to induce homo- or hetero-dimerization.
Future studies correlating this with changes in the phosphorylation of specific tyrosine
residues on the EGF receptor will be required to determine the ability of these ligands to
initiate a particular signaling pathway.

Previous studies indicate that AR may not

stimulate the phosphorylation of the EGF receptor on Y1045 as well as EGF, possibly
linking this ligand to reduced downregulation of the EGF receptor (154). It has been
previously proposed that the differential phosphorylation patterns stimulated by a
particular ligand may reflect subtle differences in the extracellular and intracellular
domain interface upon binding of different ligands (Figure 4.9) (47, 138). Such subtle
differences in the dimerization arm have been observed in crystal structures of the EGF
receptor extracellular domain bound to EGF or TGF-α (32, 33). The data presented here
are consistent with such a model in which ligand-induced dimerization is altered first on
the extracellular domain interface. In addition to different EGF-like ligands initiating
differences in the dimerization interfaces, the ligands may also selectively induce
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formation of dimers or higher-order oligomers (138). This could conceivably alter the
ability of the luciferase complementation assay to report on ligand-induced dimerization
and could indicate the predominance of higher-order oligomers on stimulation with
ligands other than EGF.
Conformational changes in the intracellular domain of the EGF receptor were also
analyzed following addition of either EGF or BTC using the luciferase assay. The
decrease in luciferase activity was very similar in cells treated with either EGF or BTC.
However, cells treated with BTC displayed a clear enhancement in the magnitude of the
recovery of luciferase activity. In Chapters 2 and 3 this recovery was shown to be
dependent on MAP kinase activity (Figures 2.12, 2.13, and 3.8). Loss of MAP kinase
activity completely ablated the recovery in luciferase activity. BTC has been reported to
stimulate enhanced MAP kinase phosphorylation in cells compared EGF (142). This
enhanced phosphorylation was mediated by enhanced phosphorylation of the EGF
receptor on Y1068 and ultimately resulted in an inhibition of apoptosis in cells stimulated
with BTC. The finding that BTC enhances MAP kinase phosphorylation is entirely
consistent with the data presented here in which an enhanced recovery was observed
compared to cells treated with EGF. It will be interesting to determine if BTC also
enhances phosphorylation of the EGF receptor on Thr-669 and causes increased
desensitization of the tyrosine kinase activity of the EGF receptor.
The results described in this chapter show that EGF-like ligands exhibit
differences in the ability to induce EGF receptor homo- and hetero-dimerization and in
the ability to induce intracellular domain conformational changes. This assay could be
used in future studies to further examine the dimerization potential of additional EGF-like
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ligands, as well as the ability of other ligands to affect changes in the EGF receptor
intracellular domain, particularly through modulation of the MAP kinase pathway.
Experimental Procedures
Reagents—Murine EGF (Biomedical Technologies, Inc.), murine amphiregulin
(Leinco Technolgies, Inc.), and human betacellulin (Sigma) were dissolved in sterile
water. Doxycycline was purchased from Clontech and was dissolved in sterile water. Dluciferin was from BioSynth and was dissolved in PBS. Coelenterazine was from Sigma
and was dissolved in ethanol.
DNA constructs—The ΔC-EGFR-NLuc and ΔC-EGFR-CLuc and full-length
EGFR-NLuc and EGFR-CLuc constructs were described previously in Chapter 2 (128).
ΔC-ErbB2-CLuc (pcDNA6/V5-His B, Invitrogen) was made by inserting a BsiWI site
just beyond the transmembrane domain in the ErbB2 pcDNA3.1 (+) construct (kind gift
from Dr. G. Carpenter, Vanderbilt University) using QuikChange site-directed
mutagenesis. The mutant was digested with the NheI and BsiWI restriction enzymes and
was ligated into the ΔC-EGFR-CLuc (pcDNA6/V5-His B) construct digested with the
same enzymes. This resulted in the following linker between the transmembrane domain
and CLuc fragment: QQKTYASRGGGSSGGG (100, 101). The construct was verified
by sequencing.
The ΔC-ErbB2-NLuc (pBI-Tet MCSI, Clontech) construct was generated by
digesting the ΔC-ErbB2-CLuc (pcDNA6/V5-His B) construct with NheI and BsiWI. The
insert was ligated into the ErbB2-NLuc pBI-Tet construct digested with the same
enzymes. The truncation was verified by sequencing.
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Cell Lines—CHO-K1 Tet-On cells (Clontech) were stably co-transfected with
ΔC-EGFR-NLuc and pTK-Hyg (Clontech) using Lipofectamine 2000 (Invitrogen).
Stable clones were isolated by selection in DMEM containing 600 µg/ml hygromycin
(InvivoGen). Double-stable cell lines were established by stably transfecting the ΔCEGFR-NLuc cells with either ΔC-EGFR-CLuc or ΔC-ErbB2-CLuc.

Clones stably

expressing ΔC-EGFR-CLuc were selected in DMEM containing 400 µg/ml Zeocin
(Invitrogen). The ΔC-EGFR-NLuc/CLuc cells were grown in DMEM containing 10%
FetalPlex, 1000 µg/ml penicllin/streptomycin, 100 µg/ml G418, 50 µg/ml hygromycin,
and 100 µg/ml Zeocin. Clones stably expressing ΔC-ErbB2-CLuc were selected in
DMEM containing 10 µg/ml Blasticidin (InvivoGen). Cells were grown in DMEM with
1000 µg/ml penicllin/streptomycin, 100 µg/ml G418, 50 µg/ml hygromycin, and 2 µg/ml
Blasticidin. For the transient transfection experiments with the ΔC-EGFR-NLuc, ΔCEGFR-CLuc, ΔC-ErbB2-NLuc, and ΔC-ErbB2-CLuc constructs, cells were transfected
24 hrs prior to imaging using Lipofectamine 2000. Transfection efficiency was assessed
by co-transfecting renilla luciferase (pRLuc-N1, Packard Bioscience).
Luciferase complementation imaging—48 hr prior to use cells were plated at 5
x103 cells per well in DMEM containing doxycycline in a black-walled 96-well plate.
On the day of the assay, cells were serum-starved for 2 hr and then incubated for 20 min
in 175 µl DMEM without phenol red, containing 1 mg/ml BSA, 25 mM Hepes, and 0.6
mg/ml D-luciferin at 37°C. To establish a baseline, cell radiance (photons/second/cm2/sr)
was measured using a cooled CCD camera and imaging system at 37°C (IVIS 50;
Caliper) (30 sec exposure; binning, 8; no filter; f-stop, 1; field of view, 12 cm). EGF was
added in a volume of 25 µl in the same media (DMEM, 1mg/ml BSA, 25mM Hepes,
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0.6mg/ml D-Luciferin). Radiance was measured sequentially as described above. For
experiments involving transient transfection, the transfection efficiency was assessed by
monitoring renilla luciferase expression. Media was replaced on cells with DMEM (no
phenol red) containing 1 mg/ml BSA, 25 mM Hepes, and 400 nM coelenterazine.
Radiance was immediately measured as described above except the filter was set to <510.
Data Analysis—Data was collected in quadruplicate for each condition. A flatfield correction was done to correct for differences in the baseline photon flux. Light
production expressed as photon flux (photons/sec) was determined from regions-ofinterest defined over wells using LIVINGIMAGE (Xenogen) and IGOR (Wavemetrics)
software. Changes in photon flux were calculated by subtracting values from untreated
cells from those of EGF-treated cells. Standard errors were determined using the formula
for the unpooled standard error.
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Table 4.1. Comparison of the Ymax and EC50 values following stimulation with EGF or
BTC in cells expressing ΔC-EGFR-NLuc/CLuc or ΔC-EGFR-NLuc/ΔC-ErbB2-CLuc.
The Ymax values were compared using GraphPad Prism and there was no difference
between 10 nM and 25 nM for each ligand (p-value > 0.05).
ΔC-EGFR-NLuc/CLuc
EGF
BTC
Ymax
(p/s)

ΔC-EGFR-NLuc/ ΔC-ErbB2-CLuc
EGF
BTC

10 nM

2.50 ± 0.02 x106

1.45 ± 0.01 x106

1.39 ± 0.11 x105

1.07 ± 0.04 x105

25 nM

2.54 ± 0.01 x106

1.47 ± 0.03 x106

1.50 ± 0.04 x105

1.00 ± 0.02 x105

EC50

1.8 nM (95% CI
1.5-2.1 nM)

0.8 nM (95% CI
0.5-1.2 nM)

0.7 nM (95% CI
0.2-2 nM)

1 nM (95% CI
0.3-2.8 nM)

Table 4.2. Comparison of the effects of EGF, BTC, and AR on cells expressing ΔCEGFR-NLuc/CLuc or ΔC-EGFR-NLuc/ΔC-ErbB2-CLuc. Curves were fit to a one-phase
exponential association curve using GraphPad Prism and the resulting parameters for
Ymax, rate (k), and t1/2 are reported below.

10
nM

25
nM

Ymax (p/s)
Rate (k,
min-1)
t1/2 (min)
Ymax (p/s)
Rate (k,
min-1)
t1/2 (min)

ΔC-EGFR-NLuc/CLuc
EGF
BTC
AR
1.36 ±
7.48 ±
ND
0.01 x106
0.06 x105
0.161 ±
0.188 ±
ND
0.004
0.004
4.32
3.69
ND
1.23 ±
7.00 ±
5.50 ±
0.01 x106
0.04 x105
0.04 x105
0.259 ±
0.316 ±
0.334 ±
0.006
0.007
0.012
2.67
2.19
2.08

107

ΔC-EGFR-NLuc/ ΔC-ErbB2-CLuc
EGF
BTC
AR
2.04 ±
1.51 ±
ND
0.01 x105
0.01 x105
0.263 ±
0.29 ±0.01
ND
0.006
2.64
2.43
ND
2.00 ±
1.47 ±
6.62 ±
0.01 x105
0.01 x105
0.10 x104
0.360 ±
0.444 ±
0.636 ±
0.012
0.021
0.068
1.93
1.56
1.09

Figure 4.1. Complexity of the EGF receptor family signaling network. Schematic
representation of the ligands belonging to the EGF-like growth factor family, as well as
the possible combinations of EGF receptor family homo- and hetero-dimerization
partners. The complexity of this signaling network is exemplified by the activation of
diverse signaling pathways that ultimately lead to diverse biological outcomes (Figure
from (140)).
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Figure 4.2. Ability of EGF, BTC, and AR to induce an increase in luciferase activity
in ΔC-EGF receptor cells. CHO-K1 Tet-On cells stably expressing the ΔC-EGFRNLuc and ΔC-EGFR-CLuc constructs were plated at 5x103 cells/well 48 hrs prior to
imaging in 96-well plates containing 1 µg/ml doxycycline. On the day of imaging, cells
were serum-starved for 2 hrs followed by pre-treatment with 0.6 mg/ml D-Luciferin. A,
C, E) Photon flux (photons/sec; p/s) in the absence of ligand. B, D, E) Change in photon
flux (photons/sec; p/s) following addition of increasing concentrations of EGF, BTC, or
AR, respectively. Error bars represent the standard error of data collected in
quadruplicate.
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B
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Figure 4.3. Dose-response to EGF, BTC, and AR in ΔC-EGF receptor cells. CHOK1 Tet-On cells stably expressing ΔEGFR-NLuc and ΔEGFR-CLuc were plated at 5x103
cells per well in a 96-well plate 48 hrs prior to imaging in media containing 1 µg/ml
doxycycline. Cells were serum-starved 2 hr prior to imaging. 0.6 mg/ml D-luciferin was
added to cells 20 min before imaging. These data represent the change in photon flux
(photons/sec; p/s) at the 20 min imaging time point (Figure 4.2) after stimulation with
increasing concentrations of EGF (A), BTC (B), or AR (C). The EGF (A) and BTC (B)
data were fit to a sigmoidal dose-response curve using the GraphPad Prism software
(EC50 values reported in Table 4.1). The curve through the AR data points (C) represents
the data fit to a guassian distribution, with no quantitative measurements taken from this
curve fit. Error bars represent the standard error of data collected in quadruplicate.
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Figure 4.4. Characterization of ΔC-ErbB2-NLuc and ΔC-ErbB2-CLuc constructs.
CHO-K1 Tet-On cells were plated at 5x103 cells/well in a 96-well plate 48 hrs before
imaging in DMEM containing 1 µg/ml doxycycline. 24 hrs prior to imaging, cells were
transiently transfected with the cDNA encoding ΔC-EGFR-NLuc, ΔC-EGFR-CLuc, ΔCErbB2-NLuc, and ΔC-ErbB2-CLuc in the specified combinations. On the day of
imaging, cells were serum-starved for 2 hrs, followed by a 20 min pre-treatment with 0.6
mg/ml D-Luciferin. A, C, E, G) Basal photon flux (photons/sec; p/s) for the indicated
combinations of receptors. B, D, F, H) Change in photon flux (photons/sec; p/s)
following addition of 10 nM EGF for the indicated receptor combinations. Error bars
represent standard error of quadruplicate samples.
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Figure 4.5. Ligand-induced increase in luciferase activity in ΔC-EGF receptor/ΔCErbB2 cells. CHO-K1 Tet-On cells stably transfected with ΔC-EGFR-NLuc/ΔC-ErbB2CLuc were plated at 5x103 cells/well in DMEM containing 1 µg/ml doxycycline 48 hrs
prior to imaging. On the day of imaging cells were serum-starved 2 hrs and were pretreated for 20 min with 0.6 mg/ml D-luciferin. A, C, E) Photon flux (photons/sec; p/s) in
the absence of ligand. B, D, F) Change in photon flux (photons/sec; p/s) upon addition of
increasing concentrations of EGF (B), BTC (D), or AR (F). Error bars represent the
standard error of four measurements.
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Figure 4.6. Dose-response to EGF and BTC in ΔC-EGF receptor/ΔC-ErbB2 cells.
CHO-K1 Tet-On cells stably expressing ΔC-EGFR-NLuc/ΔC-ErbB2-CLuc were plated
48 hrs prior to imaging at 5x103 cells/well in DMEM containing 1 µg/ml doxycycline.
On the day of imaging, cells were serum-starved for 2 hrs, followed by a 20 min preincubation with 0.6 mg/ml D-luciferin. Data presented here (from Figure 4.5) represent
the change in photon flux (photons/sec; p/s) at the 20 min imaging point following
addition of varying concentrations of EGF (A) or BTC (B). Data were fit to a sigmoidal
dose-response curve using GraphPad Prism, with the EC50 values listed in Table 4.1.
Error bars represent the standard error from quadruplicate measurements.
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Figure 4.7. Ligand-induced changes in luciferase activity in cells expressing ΔCEGF receptor alone or in addition to ΔC-ErbB2. CHO-K1 Tet-On cells stably
expressing either ΔC-EGFR-NLuc/ΔC-EGFR-CLuc or ΔC-EGFR-NLuc/ΔC-ErbB2CLuc were plated at 5x103 cells/well in 96-well plates containing 1 µg/ml doxycycline 48
hrs prior to imaging. Cells were serum-starved 2 hrs on the day of the assay, followed by
a 20 min pre-incubation period with 0.6 mg/ml D-luciferin. A, D) Photon flux
(photons/sec; p/s) in the absence of ligand. B, C) Change in photon flux (photons/sec;
p/s) in ΔC-EGFR-NLuc/ΔC-EGFR-CLuc cells following addition of 10 nM EGF or BTC
or 25 nM EGF, BTC, or AR. D, F) Change in photon flux (photons/sec; p/s) in ΔCEGFR-NLuc/ΔC-ErbB2-CLuc cells after addition of 10 nM EGF or BTC or 25 nM EGF,
BTC, or AR. Standard error was determined based on quadruplicate measurements.
Ligand-treated data were fit to a one-phase exponential association curve using GraphPad
Prism. Results are listed in Table 4.2.
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Figure 4.8. Effect of EGF and BTC on the ligand-induced conformational changes
in the full-length EGF receptor.
CHO-K1 Tet-On cells stably expressing EGFR-NLuc and EGFR-CLuc were plated at
5x103 cells/well in a 96-well plate 48 hrs prior to imaging in DMEM containing 1 µg/ml
doxycycline. 2 hrs prior to imaging cells were serum-starved and 20 min prior to
imaging cells were treated with 0.6 mg/ml D-luciferin. A) Basal photon flux
(photons/sec; p/s). B-F) Change in photon flux (photons/sec; p/s) after addition of
increasing concentrations of either EGF (open circles) or BTC (closed circles). Error
bars represent the standard error of measurements made in quadruplicate.
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Figure 4.9. Model for differential regulation of EGF receptor dimerization,
signaling, and biological effect mediated by different ligands. Schematic diagram
indicating potential differences in ligand binding conformations to the extracellular
domain of the EGF receptor (A and B). This extracellular difference in ligand binding
may be propagated through the transmembrane region to the intracellular domain,
mediating additional subtle differences in the binding interface. This could lead to
phosphorylation of different tyrosine resides on the C-terminal tail of the EGF receptor,
as well as recruitment of different downstream signaling proteins. Ultimately, the
differences in ligand-receptor conformation at the cell surface could be propagated to
elicit differences in the biological outcome of the cell (e.g. proliferation versus invasion)
(From (47)).
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CHAPTER 5. Discussion and Future Directions
Contributions to the EGF receptor field
In this thesis, I have described the development and utilization of a firefly
luciferase fragment complementation imaging assay to examine the dynamics of the EGF
receptor. This assay was used in two major ways: measuring the extracellular-domainmediated dimerization and the conformational changes of the intracellular domains.
Imaging an EGF receptor truncated just beyond the transmembrane domain followed
ligand-induced EGF receptor dimerization. The ability of this assay to accurately follow
the kinetics of ligand-induced dimerization in live cells is an improvement over existing
assays that are performed under sub-optimal conditions and are unable to recapitulate the
kinetics of ligand binding and dimerization.
Imaging the truncated EGF receptor in the context of homo- and heterodimerization with ErbB2 allowed detection of the differences in dimerization rate and
extent of dimerization following stimulation with different EGF-like growth factors.
These data compared the ability of these ligands to induce EGF receptor homo- and
hetero-dimerization. In addition, amphiregulin was identified to have an unique ability to
function as both an agonist and antagonist of dimerization.
Lucifease complementation imaging of the full-length EGF receptor identified
sequential ligand-induced conformational changes that required kinase activity— a
ligand-induced decrease followed by a recovery in luciferase activity. Several EGF
receptor mutants were characterized to demonstrate that the decrease in luciferase activity
involved re-arrangement of the kinase domains of the EGF receptor, while the recovery
in luciferase activity was completely dependent on MAP kinase activity.
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The intriguing dependence of the recovery in luciferase activity on MAP kinase
activity is consistent with the previous reports that MAP kinase phosphorylation of the
EGF receptor on Thr-669 results in desensitization of the kinase activity of the receptor.
However, the mechanistic basis for the MAP kinase-dependent desensitization was
unknown. In this thesis, I have established a model to explain how phosphorylation of
the EGF receptor on Thr-669 results in desensitized kinase activity. Acidic amino acids
in the C-lobe of the kinase domain were identified that lie in close proximity to the Thr669 phosphorylation site on the juxtamembrane domain of the other kinase domain in an
asymmetric dimer. The data presented here strongly suggest that these residues mediate a
charge repulsion event with a phosphorylated Thr-669, resulting in a block in the
allosteric asymmetric dimer that is required for kinase activation.

This discovery

underscores the critical role that the asymmetric dimer plays in mediating the kinase
activity of the receptor and how this step in the receptor activation mechanism likely
serves as an extremely important regulatory node in the EGF receptor signaling network.
Future Directions
The luciferase complementation imaging EGF receptor system provides a myriad
of avenues for future research into the biology of the EGF receptor family. I will try and
highlight a few of the ideas that I have regarding future studies with this assay. Given
that the ErbB family members are validated cancer targets (48, 57, 66, 140, 151), one
immediate application that carries promising clinical relevance would be its utility as a
high-throughput screening assay to search for novel inhibitors of the EGF receptor with
potential to expand current therapeutic strategies. For example, the luciferase
complementation imaging assay with the truncated EGF receptor provides an excellent
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opportunity to identify novel small molecule therapeutics targeting EGF receptor
dimerization (R. Yang et al., manuscript submitted).
Small molecule inhibitors of EGF receptor family dimerization could also serve
as chemical probes to further understand the biology of these receptors. For instance, it
has been suggested that the EGF receptor and its family members not only exist as
dimers, but also as higher-order oligomers.

Inhibitors that target the “traditional”

dimerization arm/interface could be used to examine alternative interfaces that may
mediate higher-order oligomer formation.

The luciferase complementation imaging

assay is an excellent platform in which to identify small molecules targeting specific
pairs of EGF receptor family homo- and hetero-dimers.
Lucifease complementation imaging with the full-length EGF receptor provides
an opportunity to investigate the intracellular domain conformational changes that take
place following ligand binding. The comparative analysis of the MAP kinase-mediated
recovery in lucifease activity upon stimulation with EGF and betacellulin could lead to
further characterization of other ligands in the same context.
I have demonstrated that MAP kinase is able to modulate the final conformation
adopted by the EGF receptor, with the read-out being a recovery in luciferase activity.
This recovery represents a dissociation of the asymmetric kinase dimer. I feel it would
particularly interesting to apply a data-driven approach to this system to try and identify
additional modulators of the recovery in luciferase activity. RNAi screening could be
used with the full-length EGF receptor cells to identify proteins that are required for the
recovery in luciferase activity.

Besides MAP kinase, the MIG6 protein is likely a

modulator of the recovery in lucifease activity, since it has been shown to block
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formation of the asymmetric dimer interface (89, 90, 92).

It appears that blocking

asymmetric dimer formation may be a common mechanism to desensitize the kinase
activity of the EGF receptor. Therefore, identification of additional asymmetric dimer
interface modulators may provide additional insight into not only the biology of the ErbB
receptors, but also expansion of therapeutic strategies.
Finally, the luciferase complementation imaging assay could be used to study the
conformational changes in the intracellular domain of EGF receptor family heterodimers.
Preliminary data not discussed here suggest that the luciferase activity of an EGF
receptor/ErbB2 full-length hetero-dimer exhibits a similar pattern of a decrease and
recovery in luciferase activity. It will be of interest to determine if there are receptor
combinations that do not exhibit these characteristics. Particularly interesting may be the
ErbB2/ErbB3 heterodimer in which ErbB2 lacks a known ligand and ErbB3 is
intrinsically kinase-dead. This heterodimer may exhibit differences in the intracellular
domain conformational changes, particularly because this complex signals more readily
via the PI3-kinase pathway due to the presence of multiple phospho-tyrosine sites on
ErB3 that couple to this pathway.
I hope that I have highlighted not only the contributions this work has made to the
EGF receptor field, but also the potential future contributions through the use of
luciferase complementation imaging. This assay has provided a powerful tool to study
the unique and complex protein-protein interactions that occur in the EGF receptor.
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